This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Miescher S, Whiteside TL, de Tribolet N, von Fliedner V: In situ characterization, clonogenic potential, and anti-tumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68: 438–448, 1988.
Ruiter DJ, Bhan AK, Harrist TJ, Sober AJ, Mihm JC Jr: Major histocompatibility antigens and mononuclear inflammatory infiltrates in benign nevomelanocytic proliferations and malignant melanoma. J Immunol 129: 2808–2815, 1982.
Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K: Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: An immunoperoxidase study with anti-human T-and B-cell sera. Cancer 49: 1456–1464, 1982.
Kornstein MJ, Brooks JS, Elder DE: Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res 43: 2749–2753, 1983.
von Hanwehr RI, Hofman FM, Taylor CR, Apuzzo ML: Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors: Characterization of cell subsets with monoclonal antibodies. J Neurosurg 60: 1138–1147, 1984.
Hiratsuka H, Imamura M, Kasai K, Kamiya H, Ishii Y, Kohama G, Kikuchi K: Lymphocyte subpopulations and T-cell subsets in human oral cancer tissues: Immunohistologic analysis by monoclonal antibodies. Am J Clin Pathol 81: 464–470, 1984.
Rowe CJ, Beverley PC: Characterization of breast cancer infiltrate using monoclonal antibodies to human leukocyte antigens. Br J Cancer 49: 149–159, 1984.
Paine JT, Handa H, Yamasaki T, Yamashita J, Miyatake S: Immunohistochemical analysis of infiltrating lymphocytes in central nervous system tumors. Neurosurg 18
Stevens A, Kloter I, Roggendorf W: Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 61: 738–743, 1988.
Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J: Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 12: 1463–1466, 1992.
Dietl J, Horny HP, Ruck P, Kaiserling E: Dysgerminoma of the ovary. An immunohistochemical study of tumor-infiltrating lymphoreticularcells and tumor cells. Cancer 71: 2562–2568, 1993.
Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, Bokowski RM: Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferongamma secretion, and proliferation. J Immunother Emph Tumor Immunol 15: 91–104, 1994.
Maccalli C, Mortarini R, Parmiani G, Anichini A: Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int J Cancer 57: 56–62, 1994.
Zhang BX: Obsevation on the phenotypic changes of tumor-infiltrating lymphocytes (TIL) during cultivation in vitro. Chinese J Pathol 21: 281–283, 1992.
Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, Rosenberg SA: T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc Natl Acad Sci USA 91: 2829–2833, 1994.
Kuppner MC, Hamou MF, de Tribolet N: Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res 48: 6926–6932, 1988.
Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1321, 1986.
Sensi M, Salvi S, Castelli C, Maccali C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M, Parmiani G, Anichini A: T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR β chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 178: 1231–1246, 1993.
Peoples GE, Yoshino I, Douville CC, Andrews JV, Goedegebuure PS, Eberlein TJ: TCR V β 3+ and V β 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J Immunol 152: 4993–4999, 1994.
Rodolfo M, Castelli C, Bassi C, Accornero P, Sensi M, Parmiani G: Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors. Int J Cancer 57: 440–447, 1994.
Zocchi MR, Ferrarini M, Migone N, Casorati G: T-cell receptor V delta gene usage by tumour reactive gamma delta T lymphocytes infiltrating human lung cancer. Immunol 81: 234–239, 1994.
Schrier PI, Bernards R, Vaessen RTMJ, Houweling A, van der Eb AJ: Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 305: 771–775, 1983.
Becker JC, Termeer C, Schmidt RE, Brocker EB: Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 151: 7224–7232, 1993.
Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA: Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26: 95–100, 1988.
Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-beta: biological function and chemical structure. Science 233: 532–534, 1986.
Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G: Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 34: 241–251, 1992.
Cepek KL, Parker CM, Madara JL, Brenner MB: Integrin aEb7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 150: 3459–3470, 1993.
Gelb AB, Smoller BR, Warnke RA, Picker LJ: Lymphocytes infiltrating primary cutaneous neoplasms selectively express the cutaneous lymphocyte-associated antigen (CLA). Amer J Pathol 142: 1556–1564, 1993.
Roberts AI, O’Connell SM, Ebert EC: Intestinal intra-epithelial lymphocytes bind to colon cancer cells by HML-1 and CD11a. Cancer Res 53: 1608–1611, 1993.
Ward PA, Varani J: Mechanisms of neutrophil-mediated injury. 5th International ANCA Workshop, 1993.
Yamamoto H, Hirayama M, Genyea C, Kaplan J: TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes. J Immunol 152: 3842–3847, 1994.
Chatani Y, Tanimura S, Miyoshi N, Hattori A, Sato M, Kohno M: Cell type-specific modulation of cell growth by transforming growth factor beta 1 does not correlate with mitogen-activated protein kinase activation. J Biol Chem 270: 30686–30692, 1995.
Tamada K, Harada M, Ito O, Takenoyama M, Mori T, Matsuzaki G, Nomoto K: The emergence of non-cytolytic NK1.1+ T cells in the long-term culture of murine tumour-infiltrating lymphocytes: a possible role of transforming growth factor-beta. Immunology 89: 627–635, 1996.
Shemesh J, Ehrlich R: Aberrant biosynthesis and transport of class I major histocompatibility complex molecules in cells transformed with highly oncogenic human adenoviruses. J Biol Chem 268: 15704–15711, 1993.
Becker JC, Brocker EB: Lymphocyte-melanoma interaction: role of surface molecules. Recent Results Cancer Res 139: 205–214, 1995.
Kleinman GM, Zagzag D, Miller DC: Diagnostic use of immunohistochemistry in neuropathology. Neurosurg Clin N Am 5: 97–126, 1994.
Szymas J: Diagnostic immunohistochemistry of tumors of the central nervous system. Folia Neuropathol 32: 209–214 1994.
Taylor CR: Quality assurance and standardization in immunohistochemistry. A proposal for the annual meeting of the Biological Stain Commission, June, 1991. Biotech Histochem 67: 110–117, 1992.
Stemmer-Rachamimov AO, Louis DN: Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr Opin Oncol 9: 230–234, 1997.
Jay V, Edwards V, Halliday W, Rutka J, Lau R: “Polyphenotypic” tumors in the central nervous system: problems in nosology and classification. Pediatr Pathol Lab Med 17: 369–389, 1997.
Beckmann MJ, Prayson RA: A clinicopathologic study of 30 cases of oligoastrocytoma including p53 immunohistochemistry. Pathology 29: 159–164, 1997.
Krouwer HG, van Duinen SG, Kamphorst W, van der Valk P, Algra A: Oligoastrocytomas: a clinicopathological study of 52 cases. J Neurooncol 33: 223–238, 1997.
Hirose T, Schneithauer BW, Lopes MB, Gerber HA, Altermatt HJ, VandenBerg SR: Ganglioglioma: an ultrastructural and immunohistochemical study. Cancer 79: 989–1003, 1997.
Baker DL, Molenaar WM, Trojanowski JQ, Evans AE, Ross AH, Rorke LB, Packer RJ, Lee VM, Pleasure D: Nerve growth factor receptor expression in peripheral and central neuroectodermal tumors, other pediatric brain tumors, and during development of the adrenal gland. Am J Pathol 139: 115–122, 1991.
Kokunai T, Sawa H, Tamaki N: Functional analysis of trk proto-oncogene product in medulloblastoma cells. Neurol Med Chir 36: 796–804, 1996.
Pruim J, Willemsen AT, Molenaar WM, van Waarde A, Paans AM, Heesters MA, Go KG, Visser GM, Franssen EJ, Vaalburg W: Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 197: 221–226, 1995.
de Wolde H, Pruim J, Mastik MF, Koudstaal J, Molenaar WM: Proliferative activity in human brain tumors: comparison of histopathology and L-[1-(11)C]tyrosine PET. J Nucl Med 38: 1369–1374, 1997.
Sallinen P, Miettinen H, Sallinen SL, Haapasalo H, Helin H, Kononen J: Increased expression of telomerase RNA component is associated with increased cell proliferation in human astrocytomas. Am J Pathol 150: 1159–1164, 1997.
Kyritsis AP, Bondy ML, Hess KR, Cunningham JE, Zhu D, Amos CJ, Yung WK, Levin VA, Bruner JM: Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1: 1617–1622, 1995.
Korshunov AG, Sycheva RV: An immunohistochemical study of the expression of the oncoprotein p53 in astrocytic gliomas of the cerebral hemispheres. Arkh Patol 58: 37–42, 1996.
Bhattacharjee MB, Bruner JM: p53 protein in pediatric malignant astrocytomas: a study of 21 patients. J Neurooncol 32: 225–233, 1997.
Ng HK, Lo SY, Huang DP, Poon WS: Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology 26: 1–5, 1994.
Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in tumor progression. Anticancer Res 17: 1187–1194, 1997.
Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180–185, 1997.
Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217–223, 1996.
Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75: 1269–1278, 1997.
Hagel C, Laking G, Laas R, Scheil S, Jung R, Milde-Langosch K, Stavrou DK: Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas. Eur J Cancer 32A: 2242–2248, 1996.
Packham G, Cleveland J: c-Myc and apoptosis. Biochim Biophys Acta 1242: 11–28, 1995.
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849–852, 1993.
Strasser A, Harris AW, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329–339, 1994.
Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD: Expression of p53 related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 32: 1157–1165, 2001.
Matsumoto T, Fujii T, Yabe M, Oka K, Hoshi T, Sato K: MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults. Histopathology 33: 446–452, 1998.
Bodey B, Bodey B JR, Gröger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: Clinical and therapeutical significance. Anticancer Res 17:1311–1318, 1997.
Fuchs EJ, McKenna KA, Bedi A: p53-dependent DNA damage-induced apoptosis requires Fas-APO-1-independent activation of CPP321. Cancer Res 57: 2550–2554, 1997.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88–91, 1996.
Naumowski L, Clearly ML: Bcl-2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells. Blood 83: 2261–2266, 1994.
Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7: 541–546, 1995.
Haldar S, Basu A, Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 57: 229–233, 1997.
Oltvai Z, Milliman C, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog Bax that accelerates programmed cell death. Cell 74: 609–619, 1993.
Pillai MR, Kesari AL, Chellam VG, Madhavan J, Nair P, Nair MK: Spontaneous programmed cell death in infiltrating duct carcinoma: association with p53, BCL-2, hormone receptors and tumor proliferation. Pathol Res Pract 194: 549–557, 1998.
Yuan J, Horvitz HR: The Caenorhabditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death. Dev Biol 138: 33–41, 1990.
Hengartner MO, Ellis RE, Horvitz HR: Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 356: 494–499, 1992.
Steller H: Mechanisms and genes of cellular suicide. Science 267: 1445–1448, 1995.
Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1–6, 1994.
Pourzand C, Rossier G, Reelfs O, Borner C, Tyrrell RM: The overexpression of bcl-2 inhibits UVA-mediated immediate apoptosis in rat 6 fibroblasts: evidence for the involvement of bcl-2 as an antioxidant. Cancer Res 57: 1405–1411, 1997.
Alnermi ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J: Human ICE/CED-3 protease nomenclature. Cell 87: 171, 1996.
Kumar S, Kinoshita M, Noda M, Copeland NG, Jenkins NA: Induction of apoptosis by the mouse Nedd 2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1β-converting enzyme. Genes Dev 8: 1613–1626, 1994.
Sinkovics JG: Malignant lymphoma arising from natural killer cells: report of the first case in 1970 and newer developments in the FasL FasR system. Acta Microbiol Immunol Hung 44: 295–303, 1997.
Wang L, Miura M, Bergeron B, Zhu H, Yuan J: Ich-1, an ICE/Ced-3 related gene, encodes both positive and negative regulators of programmed cell death. Cell 78: 739–750, 1994.
Kamens J, Paskind M, Hugunin M, Talanian RV, Allen H, Banach D, Bump N, Hackett M, Johnston CG, Li P, Mankovich JA, Terranova M, Ghayur T: Identification and characterization of ICH-2, a novel member of the interleukin-1 beta-converting enzyme family of cysteine proteases. J Biol Chem 270: 15250–15256, 1995.
Fernandes-Alnemri T, Litwack G, Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269: 30761–30764, 1995.
Fernandes-Alnemri T, Litwack G, Alnemri ES: Mch2, a new member of the apoptotic Ced-3/ICE cysteine protease gene family. Cancer Res 55: 2737–2742, 1995.
Munday NA, Vaillancourt JP, Ali A, Casano FJ, Miller DK, Molineaux SM, Yamin TT, Yu VL, Nicholson DW: Molecular cloning and pro-apoptotic activity of ICErelII and ICErelIII members of the ICE/Ced-3 family of cysteine proteases. J Biol Chem 270: 15870–15876, 1995.
Duan H, Chinnaiyan AM, Hudson P, Wing JP, He WW, Dixit VM: ICE-LAP3, a novel mammalian homologue of of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem 271: 1621–1625, 1996.
Duan H, Orth K, Chinnaiyan AM, Poirier GG, Froelich CJ, He WW, Dixit VM: ICE-LAP6, a novel member of the ICE-Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem 271: 16720–16724, 1996.
Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 85: 803–815, 1996.
Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346–347, 1994.
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37–43, 1995.
Sorensen CM: Apoptosis or planning a death. Biomedical Products (September, 1996 issue), pp 38–39, 1996.
Asano K, Kubo O, Tajika Y, Huang MC, Takakura K, Ebina K, Suzuki S: Expression and role of cadherins in astrocytic tumors. Brain Tumor Pathol 14: 27–33, 1997.
Huber O: Structure and function of desmosomal proteins and their role in development and disease. Cell Mol Life Sci 60: 1872–1890, 2003.
Strelkov SV, Herrmann H, Aebi U: Molecular architecture of intermediate filaments. Bioessays 25: 243–251, 2003.
Hasegawa K, Yoshida T, Matsumoto K, Katsuta K, Waga S, Sakakura T: Differential expression of tenascin-C and tenascin-X in human astrocytomas. Acta Neuropathol (Berl) 93: 431–437, 1997.
Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J: Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57: 3272–3280, 1997.
Aaronson SA: Growth factors and cancer. Science 254: 1146–1153; 1991.
Engebraaten O, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, Laerum OD: Effect of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer 53: 209–214, 1993.
Chicoine MR, Madsen CL, Silbergeld DL: Modification of human glioma locomotion in vitro by cytokines EGF, bFGF, PDGFbb, NGF, and TNFa. Neurosurg 36: 1165–1171, 1995.
U HS, Espiritu OD, Kelley PY, Klauber MR, Hatton JD: The role of the epidermal growth factor receptor in human gliomas: I. The control of cell growth. J Neurosurg 82: 841–846, 1995.
Hitotsumatsu T, Iwaki T, Kitamoto T, Mizoguchi M, Suzuki SO, Hamada Y, Fukui M, Tateishi J: Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol 93: 225–232, 1997.
Chang F, Li R, Noon K, Gage D, Ladisch S: Human medulloblastoma gangliosides. Glycobiology 7: 523–530, 1997.
Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST: Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 93: 518–527, 1997.
Ingber DE: Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res 91: 877–887, 2002.
Moffett JR, Els T, Espey MG, Walter SA, Streit WJ, Namboodiri MA: Quinolinate immunoreactivity in experimental rat brain tumors is present in macrophages but not in astrocytes. Exp Neurol 144: 287–301, 1997.
Yoon Y, Pitts K, McNiven M: Studying cytoskeletal dynamics in living cells using green fluorescent protein. Mol Biotechnol 21: 241–250, 2002.
Osborn M, Weber K: Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest 48: 372–394, 1983.
Yung WK, Luna M, Borit A: Vimentin and glial fibrillary acidic protein in human brain tumors. J Neurooncol 3: 35–38, 1985.
Gown AM, Vogel AM: Anti-intermediate filament monoclonal antibodies: tissuespecific tools in tumor diagnosis. Surv Synth Pathol Res 3: 369–385, 1984.
Cooper EH: Neuron specific enolase: a marker of (small cell) cancers of neuronal and neuroendocrine origin. Biomed Pharmacother 39: 165–166, 1985.
Gould VE: Histogenesis and differentiation: a re-evaluation of these concepts as criteria for the classification of tumors. Hum Pathol 17: 212–215, 1986.
Messing A, Brenner M: GFAP: functional implications gleaned from studies of genetically engineered mice. Glia 43: 87–90, 2003.
Eng LF, Ghirnikar RS, Lee YL: Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res 25: 1439–1451, 2000.
Rungger-Brandle E, Achtstatter T, Franke WW: An epithelium-type cytoskeleton in a glial cell: astrocytes of amphibian optic nerves contain cytokeratin filaments and are connected by desmosomes. J Cell Biol 109: 705–716, 1989.
Cosgrove M, Fitzgibbons PL, Sherrod A, Chandrasoma PT, Martin SE: Intermediate filament expression in astrocytic neoplasms. Am J Surg Pathol 13: 141–145, 1989.
Leader M, Collins M, Patel J, Henry K: Vimentin: an evaluation of its role as a tumour marker. Histopathology 11: 63–72, 1987.
Gown AM, Vogel AM: Monoclonal antibodies to human intermediate filament proteins. III. Analysis of tumors. Am J Clin Pathol 84: 413–424, 1984.
Roessmann U, Velasco ME, Gambetti P, Autilio-Gambetti L: Vimentin intermediate filaments are increased in human neoplastic astrocytes (abstract). J Neuropathol Exp Neurol 42: 309, 1983.
Wang E, Cairncross JG, Liem RK: Identification of glial filament protein and vimentin in the same intermediate filament system in human glioma cells. Proc Natl Acad Sci USA 81: 2102–2106, 1984.
Galloway PG, Roessmann U: Anaplastic astrocytoma mimicking metastatic carcinoma. Am J Surg Pathol 10: 728–732, 1986.
Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079–1087, 1990.
Perentes E, Rubinstein LJ: Recent applications of immunoperoxidase histochemistry in human neuro-oncology. An update. Arch Pathol Lab Med 111: 796–812, 1987.
Mork SJ, Rubinstein LJ, Kepes JJ, Perentes E, Uphoff DF: Patterns of epithelial metaplasia in malignant gliomas. II. Squamous differentiation of epithelial-like formations in gliosarcomas and glioblastomas. J Neuropathol Exp Neurol 47: 101–118, 1988.
Franke WW, Weber K, Osborn M, Schmid E, Freudenstein C: Antibody to prekeratin. Decoration of tonofilament like arrays in various cells of epithelial character. Exp Cell Res 116: 429–445, 1978.
Franke WW, Appelhans B, Schmid E, Freudenstein C, Osborn M, Weber K: Identification and characterization of epithelial cells in mammalian tissues by immunofluorescence microscopy using antibodies to prekeratin. Differentiation 15: 7–25, 1979.
Steinert PM, Steven AC, Roop DR: The molecular biology of intermediate filaments. Cell 42: 411–420, 1985.
Steinert PM, Roop DR: Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 57: 593–625, 1988.
Kepes JJ, Fulling KH, Garcia JH: The clinical significance of “adenoid” formations of neoplastic astrocytes, imitating metastatic carcinoma, in gliosarcomas. A review of five cases. Clin Neuropathol 1: 139–150, 1982.
Sun TT, Green H: Keratin filaments of cultured human epidermal cells. Formation of intermolecular disulfide bonds during terminal differentiation. J Biol Chem 253: 2053–2060, 1978.
Green H, Fuchs E, Watt F: Differentiated structural components of the keratinocyte. Cold Spring Harb Symp Quant Biol 46: 293–301, 1982.
Moll R, Franke WW, Schiller DL, Geiger B, Krepler R: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11–24, 1982.
Sun TT, Eichner R, Nelson WG, Tseng SC, Weiss RA, Jarvinen M, Woodcock-Mitchell J: Keratin classes: molecular markers for different types of epithelial differentiation. J Invest Dermatol 8: 109s–115s, 1983.
Steinert PM, Steven AC: Splitting hairs and other intermediate filaments. Nature 316: 767, 1985.
Fuchs E, Green H: Changes in keratin gene expression during terminal differentiation of the keratinocyte. Cell 19: 1033–1042, 1980.
Tseng SC, Jarvinen MJ, Nelson WG, Huang JW, Woodcock-Mitchell J, Sun TT: Correlation of specific keratins with different types of epithelial differentiation: monoclonal antibody studies. Cell 30: 361–372, 1982.
Moll R, von Bassewitz DB, Schulz U, Franke WW: An unusual type of cytokeratin filament in cells of a human cloacogenic carcinoma derived from the anorectal transition zone. Differentiation 22: 25–40, 1982.
Moll R, Krepler R, Franke WW: Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation 23: 256–269, 1983.
Weiss SW, Langloss JM, Enzinger FM: Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest 49: 299–308, 1983.
Debus E, Weber K, Osborn M: Monoclonal antibodies specific for glial fibrillary acidic (GFA) protein and for each of the neurofilament triplet polypeptides. Differentiation 25: 193–203, 1983.
Woodcock-Mitchell J, Eichner R, Nelson WG, Sun TT: Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol 95: 580–588, 1982.
Damjanov I: Antibodies to intermediate filaments and histogenesis. Lab Invest 47: 215–217, 1982.
Trojanowski JQ, Lee VM, Schlaepfer WW: An immunohistochemical study of human central and peripheral nervous system tumors, using monoclonal antibodies against neurofilaments and glial filaments. Hum Pathol 15: 248–257, 1984.
Sun TT, Shih C, Green H: Keratin cytoskeletons in epithelial cells of internal organs. Proc Natl Acad Sci USA 76: 2813–2817, 1979.
Zipser B, Schley C: Description of two differently distributed central nervous system antigens with single monoclonal antibody and different methods of fixation. Ann NY Acad Sci 420: 100–106, 1983.
Gabbiani G, Kapanci Y, Barazzone P, Franke WW: Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol 104: 206–216, 1981.
Vinores SA, Rubinstein LJ: Simultaneous expression of glial fibrillary acidic (GFA) protein and neuron-specific enolase (NSE) by the same reactive or neoplastic astrocytes. Neuropathol Appl Neurobiol 11: 349–359, 1985.
Lazarides E: Intermediate filaments: a chemically heterogeneous, developmentally regulated class of proteins. Annu Rev Biochem 51: 219–250, 1982.
Kemshead JT, Coakham HB: The use of monoclonal antibodies for the diagnosis of intracranial malignancies and the small round cell tumours of childhood. J Pathol 141: 249–257, 1983.
Kemshead JT: Pediatric Tumors: Immunological and Molecular Markers. Boca Roton, FL, CRC Press, 1989.
Molenaar WM, Jansson DS, Gould VE, Rorke LB, Franke WW, Lee VM, Packer RJ, Trojanowski JQ: Molecular markers of primitive neuroectodermal tumors and other pediatric central nervous system tumors. Monoclonal antibodies to neuronal and glial antigens distinguish subsets of primitive neuroectodermal tumors. Lab Invest 61: 635–643, 1989.
Gould VE, Jansson DS, Molenaar WM, Rorke LB, Trojanowski JQ, Lee VM, Packer RJ, Franke WW: Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins. Lab Invest 62: 498–509, 1990.
Dahl D, Bignami A: Astroglial and axonal proteins in isolated brain filaments. I. Isolation of the glial fibrillary acidic protein and of an immunologically active cyanogen bromide peptide from brain filament preparations of bovine white matter. Biochim Biophys Acta 578: 305–316, 1979.
Sawa H, Takeshita I, Kuramitsu M, Fukui M, Inomata H: Immunohistochemistry of retinoblastomas. J Neurooncol 5: 351–355, 1987.
Dahl D: Isolation of neurofilament proteins and of immunologically active neurofilament degradation products from extracts of brain, spinal cord and sciatic nerve. Biochim Biophys Acta 668: 299–306, 1981.
Wang N, Stamenovic D: Mechanics of vimentin intermediate filaments. J Muscle Res Cell Motil 23: 535–540, 2002.
Helfand BT, Chang L, Goldman RD: The dynamic and motile properties of intermediate filaments. Annu Rev Cell Dev Biol 19: 445–467, 2003.
Bürglin TR: Homeodomain Proteins. In: Encyclopedia of Molecular Biology and Molecular Medicine (Meyers RA, ed). Vol 3. Weinheim, VCH Verlagsgesellschaft mbH, p1996, pp 55–76.
Stornaiuolo A, Acampora D, Pannese M, D’Esposito M, Morelli F, Migliaccio E, Rambaldi M, Faiella A, Nigro V, Simeone A, Boncinelli E: Human HOX genes are differentially activated by retinoic acid in embryonal carcinoma cells according to their position within the four loci. Cell Differ Dev 31: 119–127, 1990.
Giampaolo A, Acampora D, Zappavigna V, Pannese M, D’Esposito M, Care A, Faiella A, Stornaiuolo A, Russo G, Simeone A, Boncinelli E, Peschle C: Differential expression of human HOX-2 genes along the anterior-posterior axis in embryonic central nervous system. Differentiation 40: 191–197, 1989.
Mavilio F, Simeone A, Boncinelli E, Andrews PW: Activation of four homeobox gene clusters in human embryonal carcinoma cells induced to differentiate by retinoic acid. Differentiation 37: 73–79, 1988.
Simeone A, Acampora D, D’Esposito M, Faiella A, Pannese M, Scotto L, Montanucci M, D’Alessandro G, Mavilio F, Boncinelli E: Posttranscriptional control of human homeobox gene expression in induced NTERA-2 embryonal carcinoma cells. Mol Reprod Dev 1: 107–115, 1989.
Peverali FA, D’Esposito M, Acampora D, Bunone G, Negri M, Faiella A, Stornaiuolo A, Pannese M, Migliaccio E, Simeone A, Della Valle G, Boncinelli E: Expression of HOX homeogenes in human neuroblastoma cell culture lines. Differentiation 45: 61–69, 1990.
Maconochie MK, Nonchev S, Studer M, Chan SK, Popperl H, Sham MH, Mann RS, Krumlauf R: Cross-regulation in the mouse HoxB complex: the expression of Hoxb2 in rhombomere 4 is regulated by Hoxb1. Genes Dev 11: 1885–1895, 1997.
Gould A, Morrison A, Sproat G, White RA, Krumlauf R: Positive cross-regulation and enhancer sharing: two mechanisms for specifying overlapping Hox expression patterns. Genes Dev 11: 900–913, 1997.
Sauvageau G, Thorsteinsdottir U, Eaves CJ, Lawrence HJ, Largman C, Lansdorp PM, Humphries RK: Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev 9: 1753–1765, 1995.
Rancourt DE, Tsuzuki T, Capecchi MR: Genetic interaction between hoxb-5 and hoxb-6 is revealed by nonallelic noncomplementation. Genes Dev 9: 108–122, 1995.
Sun J, Rose JB, Bird P: Gene structure, chromosomal localization, and expression of the murine homologue of human proteinase inhibitor 6 (PI-6) suggests divergence of PI-6 from the ovalbumin serpins. J Biol Chem 270: 16089–16096, 1995.
Hogan BL, Holland PW, Lumsden A: Expression of the homeobox gene, Hox 2.1, during mouse embryogenesis. Cell Diff Dev 25: 39–44, 1988.
Safaei R: A target of the HoxB5 gene from the mouse nervous system. Brain Res Dev Brain Res 100: 5–12, 1997.
Lawrence HJ, Sauvageau G, Humphries RK, Largman C: The role of HOX homeobox genes in normal and leukemic hematopoiesis. Stem Cells 14: 281–291, 1996.
Thorsteinsdottir U, Sauvageau G, Humphries RK: Hox homeobox genes as regulators of normal and leukemic hematopoiesis. Hematol Oncol Clin North Am 11: 1221–1237, 1997.
Shimamoto T, Ohyashiki K, Toyama K, Takeshita K: Homeobox genes in hematopoiesis and leukemogenesis. Int J Hematol 67: 339–350, 1998.
Chiba S: Homeobox genes in normal hematopoiesis and leukemogenesis. Int J Hematol 68: 343–353, 1998.
Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM: Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell Biol 15: 5434–5443, 1995.
Nakamura T, Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG: Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet 12:149–153, 1996.
Lawrence HJ, Sauvageau G, Ahmadi N, Lopez AR, LeBeau MM, Link M, Humphries K, Largman C: Stage-and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells. Exp Hematol 23: 1160–1166, 1995.
Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE: Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 13: 687–698, 1999.
Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G: Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 17: 3714–3725, 1998.
Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, Largman C, Humphries RK: Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol 17: 495–505, 1997.
Ohnishi K, Tobita T, Sinjo K, Takeshita A, Ohno R: Modulation of homeobox B6 and B9 genes expression in human leukemia cell lines during myelomonocytic differentiation. Leuk Lymphoma 31: 599–608, 1998.
Cillo C, Cantile M, Mortarini R, Barba P, Parmiani G, Anichini A: Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis. Int J Cancer 66: 692–697, 1996.
Lawrence HJ, Stage KM, Mathews CH, Detmer K, Scibienski R, MacKenzie M, Migliaccio E, Boncinelli E, Largman C: Expression of HOX C homeobox genes in lymphoid cells. Cell Growth Differ 4: 665–669, 1993.
Bijl JJ, van Oostveen JW, Walboomers JM, Brink AT, Vos W, Ossenkoppele GJ, Meijer CJ: Differentiation and cell-type-restricted expression of HOXC4, HOXC5 and HOXC6 in myeloid leukemias and normal myeloid cells. Leukemia 12: 1724–1732, 1998.
Meazza R, Faiella A, Corsetti MT, Airoldi I, Ferrini S, Boncinelli E, Corte G: Expression of HOXC4 homeoprotein in the nucleus of activated human lymphocytes. Blood 85: 2084–90, 1995.
Bijl J, van Oostveen JW, Kreike M, Rieger E, van der Raaij-Helmer LM, Walboomers JM, Corte G, Boncinelli E, van den Brule AJ, Meijer CJ: Expression of HOXC4, HOXC5, and HOXC6 in human lymphoid cell lines, leukemias, and benign and malignant lymphoid tissue. Blood 87: 1737–1745, 1996.
Bijl JJ, van Oostveen JW, Walboomers JM, Horstman A, van den Brule AJ, Willemze R, Meijer CJ: HOXC4, HOXC5, and HOXC6 expression in non-Hodgkin’s lymphoma: preferential expression of the HOXC5 gene in primary cutaneous anaplastic T-cell and oro-gastrointestinal tract mucosa-associated B-cell lymphomas. Blood 90: 4116–4125, 1997.
Bijl JJ, Rieger E, van Oostveen JW, Walboomers JM, Kreike M, Willemze R, Meijer CJ: HOXC4, HOXC5, and HOXC6 expression in primary cutaneous lymphoid lesions. High expression of HOXC5 in anaplastic large-cell lymphomas. Am J Pathol 151: 1067–1074, 1997.
Alami Y, Castronovo V, Belotti D, Flagiello D, Clausse N: HOXC5 and HOXC8 expression are selectively turned on in human cervical cancer cells compared to normal keratinocytes. Biochem Biophys Res Commun 257: 738–745, 1999.
Shim C, Zhang W, Rhee CH, Lee JH: Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. Clin Cancer Res 4: 3045–3050, 1998.
Osborne J, Hu C, Hawley C, Underwood LJ, O’Brien TJ, Baker VV: Expression of HOXD10 gene in normal endometrium and endometrial adenocarcinoma. J Soc Gynecol Investig 5: 277–280, 1998.
Boylan JF, Lohnes D, Taneja R, Chambon P, Gudas LJ: Loss of retinoic acid receptor gamma function in F9 cells by gene disruption results in aberrant Hoxa-1 expression and differentiation upon retinoic acid treatment. Proc Natl Acad Sci USA 90: 9601–9605, 1993.
Pratt MA, Langston AW, Gudas LJ, McBurney MW: Retinoic acid fails to induce expression of Hox genes in differentiation-defective murine embryonal carcinoma cells carrying a mutant gene for retinoic acid receptor. Differentiation 53: 105–113, 1993.
Langston AW, Gudas LJ: Retinoic acid and homeobox gene regulation. Curr Opin Genet Dev 4: 550–555, 1994.
Knoepfler PS, Kamps MP: The Pbx family of proteins is strongly upregulated by a post-transcriptional mechanism during retinoic acid-induced differentiation of P19 embryonal carcinoma cells. Mech Dev 63: 5–14, 1997.
Simeone A, Acampora D, Arcioni L, Andrews PW, Boncinelli E, Mavilio F: Sequential activation of HOX2 homeobox genes by retinoic acid in human embryonal carcinoma cells. Nature 346: 763–766, 1990.
Chang CP, de Vivo I, Cleary ML: The Hox cooperativity motif of the chimeric oncoprotein E2a-Pbx1 is necessary and sufficient for oncogenesis. Mol Cell Biol 17: 81–88, 1997.
Krosl J, Baban S, Krosl G, Rozenfeld S, Largman C, Sauvageau G: Cellular proliferation and transformation induced by HOXB4 and HOXB3 proteins involves cooperation with PBX1. Oncogene 16: 3403–3412, 1998.
Tiberio C, Barba P, Magli MC, Arvelo F, Le Chevalier T, Poupon MF, Cillo C: HOX gene expression in human small-cell lung cancers xenografted into nude mice. Int J Cancer 58: 608–615, 1994.
Flagiello D, Gibaud A, Dutrillaux B, Poupon MF, Malfoy B: Distinct patterns of alltrans retinoic acid dependent expression of HOXB and HOXC homeogenes in human embryonal and small-cell lung carcinoma cell lines. FEBS Lett 415: 263–267, 1997.
Flagiello D, Poupon MF, Cillo C, Dutrillaux B, Malfoy B: Relationship between DNA methylation and gene expression of the HOXB gene cluster in small cell lung cancers. FEBS Lett 380: 103–107, 1996.
Chariot A, Moreau L, Senterre G, Sobel ME, Castronovo V: Retinoic acid induces three newly cloned HOXA1 transcripts in MCF7 breast cancer cells. Biochem Biophys Res Commun 215: 713–720, 1995.
Chariot A, Castronovo V: Detection of HOXA1 expression in human breast cancer. Biochem Biophys Res Commun 222: 292–297, 1996.
Suzuki M, Tanaka M, Iwase T, Naito Y, Sugimura H, Kino I: Over-expression of HOX-8, the human homologue of the mouse Hox-8 homeobox gene, in human tumors. Biochem Biophys Res Commun 194: 187–193, 1993.
De Vita G, Barba P, Odartchenko N, Givel JC, Freschi G, Bucciarelli G, Magli MC, Boncinelli E, Cillo C: Expression of homeobox-containing genes in primary and metastatic colorectal cancer. Eur J Cancer 29A: 887–893, 1993.
Manohar CF, Furtado MR, Salwen HR, Cohn SL: Hox gene expression in differentiating human neuroblastoma cells. Biochem Mol Biol Int 30: 733–741, 1993.
Manohar CF, Salwen HR, Furtado MR, Cohn SL: Up-regulation of HOXC6, HOXD1, and HOXD8 homeobox gene expression in human neuroblastoma cells following chemical induction of differentiation. Tumour Biol 17: 34–47, 1996.
Cillo C, Barba P, Freschi G, Bucciarelli G, Magli MC, Boncinelli E: HOX gene expression in normal and neoplastic human kidney. Int J Cancer 51: 892–897, 1992.
Deschamps J, Meijlink F: Mammalian homeobox genes in normal development and neoplasia. Crit Rev Oncog 3: 117–173, 1992.
Friedmann Y, Daniel CA, Strickland P, Daniel CW: Hox genes in normal and neoplastic mouse mammary gland. Cancer Res 54: 5981–5985, 1994.
Redline RW, Hudock P, MacFee M, Patterson P: Expression of AbdB-type homeobox genes in human tumors. Lab Invest 71: 663–670, 1994.
Cillo C: HOX genes in human cancers. Invasion Metastasis 14: 38–49, 1994–-95.
Stuart ET, Yokota Y, Gruss P: PAX and HOX in neoplasia. Adv Genet 33: 255–274, 1995.
Mark M, Rijli FM, Chambon P: Homeobox genes in embryogenesis and pathogenesis. Pediatr Res 42: 421–429, 1997.
Boudreau N, Andrews C, Srebrow A, Ravanpay A, Cheresh DA: Induction of the angiogenic phenotype by Hox D3. J Cell Biol 139: 257–264, 1997.
Care A, Silvani A, Meccia E, Mattia G, Stoppacciaro A, Parmiani G, Peschle C, Colombo MP: HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol 16: 4842–4851, 1996.
Kloen P, Visker MH, Olijve W, van Zoelen EJ, Boersma CJ: Cell-type-specific modulation of Hox gene expression by members of the TGF-beta superfamily: a comparison between human osteosarcoma and neuroblastoma cell lines. Biochem Biophys Res Commun 233: 365–369, 1997.
Silverberg E, Boring CC, Squires TS: Cancer statistics, CA-A Cancer J Clinicians 40: 9–26, 1990.
Cooper GM (ed), Elements of human cancer. Jones & Bartlett Publishers, Boston-London, 1992, pp.7–14.
Katsetos CD, Krishna L, Frankfurter A, Karkavelas G, Wolfe DE, Valsamis MP, Schiffer D, Vlachos IN, Urich H: A cytomorphological scheme of differentiating neuronal phenotypes in cerebellar medulloblastomas based on immunolocalization of class III β-tubulin isotype (β III) and proliferating cell nuclear antigen (PCNA)/cyclin. Clinical Neuropathol 14: 72–81, 1995.
O’Brien MC, Gupta RK, Lee SY, Bolton WE: Use of a multiparametric panel to target subpopulations in a heterogeneous solid tumor model for improved analytical accuracy. Cytometry 21: 76–83, 1995.
Oda Y, Tsuneyoshi M: A comparative study of nuclear photometry and proliferating activity in neuroectodermal tumors of bone and Ewing’s sarcoma of bone. General & Diagnostic Pathol 141: 121–129, 1995.
Ellis PA, Makris A, Burton SA, Titley J, Ormerod MG, Salter J, Powles TJ, Smith IE, Dowsett M: Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. Brit J Cancer 73: 640–643, 1996.
Oyama T, Take H, Hikino T, Iino Y, Nakajima T: Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncol 53: 112–117, 1996.
Enzinger FM, Lattes R, Torloni H: Histological typing of soft tissue tumours. World Health Organization, Geneva, 1971, p. 28.
Kury G, Carter HW: Autoradiographic study of human nervous system tumors. Arch Pathol 80: 38–42, 1965.
Tym R: Distribution of cell doubling times in in vivo human cerebral tumors. Surg Forum 20: 445–447, 1969.
Hoshino T, Barker M, Wilson CB, Boldrey EB, Fewer D: Cell kinetics of human gliomas. J Neurosurg 37: 15–26, 1975.
Hoshino T, Wilson CB, Rosenblum ML, Barker M: Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. J Neurosurg 43: 127–135, 1975.
Böker DK, Stark HJ, Gullotta F, Nadstawek J, Schultheiss R: Immunohistochemical demonstration of the Ki-67-antigen in paraffin-embedded tumor biopsies. Clin Neuropathol 9: 51–54, 1990.
Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1(3): 199–206, 1990.
Sledge GW, Eble JN, Roth BJ, Wuhrman BP, Fineberg N, Einhorn LH: Relation of proliferate activity to survival in patients with advanced germ cell cancer. Cancer Res 48: 3864–3868, 1988.
Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillet CE, Camplejohn R, Dover R: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an insex of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285–294, 1990.
Munck-Wikland E, Fernberg JO, Kuylenstierna R, Lindholm J, Aver G: Proliferating cell nuclear antigen (PCNA) expression and nuclear DNA content in predicting recurrence after radiotherapy of glottic cancer. Oral Oncol Eur J Cancer 2913: 75–79, 1993.
Broich G, Lavezzi A-M, Biondo B, Pignataro LD: PCNA — a cell proliferation marker in vocal cord cancer. Part II: recurrence in malignant laryngeal lesions. In Vivo 10: 175–178, 1996.
Visakorpi T: Proliferative activity determined by DNA flow cytometry and proliferate cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J Pathol 168: 7–13, 1992.
Pignataro LD, Broich G, Lavezzi AM, Biondo B, Ottaviani F: PCNA — a cell proliferation marker in vocal cord cancer. Part I: Premalignant laryngeal lesions. Anticancer Res 15: 1517–1520, 1995.
Fairman MP: DNA polymerase/PCNA: Actions and interactions. J Cell Science 95: 1–4, 1990.
Bravo R, Franke Blundell PA, MacDonald M, Bravo M: Cyclin/PCNA is the auxiliary protein of the DNA polymerase delta. Nature 326: 517–518, 1987.
Cruz-Sanchez FF, Ferreres JC, Figols J, Palacin A, Cardesa A, Rossi ML, Val-Bernal JF: Prognostic analysis of astrocytic gliomas correlating histological parameters with the proliferating cell nuclear antigen labeling index (PCNA-LI). Histol Histopathol 12: 43–49, 1997.
Bodey B: The significance of immunocytochemistry in the diagnosis and therapy of neoplasms. Expert Opinion Biological Therapy 2: 371–393, 2002.
Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344: 503–508, 1990.
Pardee A: G1 events and regulation of cell proliferation. Science 246: 603–608, 1989.
Vulliet PR, Hall FL, Mitchell JP, Hardie DG: Identification of a novel proline-directed serine/threonine protein kinase in rat pheochromocytoma. J Biol Chem 264: 16292–16298, 1989.
Hall FL, Vulliet PR: Proline-directed protein phosphorylation and cell cycle regulation. Current Opinion Cell Biol 3: 176–184, 1991.
Howard A, Pelc SR: Nuclear incorporation of 32P as demonstrated by autoradiographs. Expl Cell Res 2: 178–187, 1951.
Darzynkiewicz Z: Molecular interactions and cellular changes during the cell cycle. Pharmacol Ther 21: 143–188, 1983.
Quastler H, Sherman FG: Cell population kinetics in the intestinal epithelium of the mouse. Exp Cell Res 17: 420–438, 1959.
Miyachi K, Fritzler MJ, Tan EM: Autoantibody to a nuclear antigen in proliferating cells. J Immunol 121: 2228–2234, 1978.
Tan EM: Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 33: 167–240, 1982.
Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715, 1984.
Hoshino T, Wilson CB: Cell kinetic analyses of human malignant brain tumours (gliomas). Cancer 44: 956–962, 1979.
Kirkpatrick JP, Marks LB: Modeling killing and repopulation kinetics of subclinical cancer: direct calculations from clinical data. Int J Radiat Oncol Biol Phys 58(2): 641–654, 2004.
Knobler RL, Lublin FD, Streletz LJ, Zimmer M, Joseph J, D’Imperio C, Northrup B, Barolat G, Marcus SG: Intracerebral beta-interferon in brain tumor therapy. Monitoring cerebral function with compressed spectral analysis. Ann NY Acad Sci 540: 573–575, 1988.
Hoshino T, Townsend JJ, Muraoka I, Wilson CB: An autoradiographic study of human gliomas: growth kinetics of anaplastic astrocytoma and glioblastoma multiforme. Brain 103: 967–984, 1980.
Crafts DC, Hoshino T, Wilson CB: Current status of population kinetics in gliomas. Bull Cancer. 64: 115–124, 1977.
Gerdes J: An immunohistological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery. Int J Cancer 35: 169–171, 1985.
Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715, 1984.
Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13–20, 1983.
Burger PC, Shibata T, Kleihues P: The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical pathology. Am J Surg Pathol 10: 611–617, 1986.
Ostertag CB, Volk B, Shibata T, Burger P, Kleihues P: The monoclonal antibody Ki-67 as a marker for proliferating cells in sterotactic biopsies of brain tumours. Acta Neurochirurg (Wien) 89: 117–121, 1987.
Giangaspero F, Doglioni C, Rivano MT, Pileri S, Gerdes J, Stein H: Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67. Acta Neuropathol (Berlin) 74: 179–182, 1987.
Zuber P, Hamou MF, De Tribolet N: Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 22: 364–368, 1988.
Roggendorf W, Schuster T, Peiffer J: Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol (Berlin) 73: 361–364, 1987.
Pileri S, Gerdes J, Rivano M, Tazzari PL, Magnani M, Gobbi M, Stein H: Immunohistochemical determination of growth fractions in human permanent cell lines and lymphoid tumors: a critical comparison of the monoclonal antibodies OKT9 and Ki-67. Brit J Haematol 65: 271–276, 1987.
Lloyd RV, Wilson BS, Varani J, Gaur PK, Moline S, Makari JG: Immunocytochemical characterization of a monoclonal antibody that recognizes mitosing cells. Amer J Pathol 121: 275–283, 1985.
Klein G, Steiner M, Wiener F, Klein E: Human leukemia-associated anti-nuclear reactivity. Proc Natl Acad Sci USA 71: 685–689, 1974.
Boker DK, Stark HJ: The proliferation rate of intracranial tumors as defined by the monoclonal antibody KI 67. Application of the method to paraffin embedded specimens. Neurosurg Rev 11: 267–272, 1988.
Murry AW, Kirschner M: Cyclin synthesis drives the early embryonic cell cycle. Nature 339: 275–280, 1989.
Hall FL, Braun RK, Mihara K, Fung YK, Berndt N, Carbonaro-Hall DA, Vulliet PR: Characterization of the cytoplasmic proline-directed protein kinase in proliferative cells and tissues as a heterodimer comprised of p34cdc2 and p58cyclin A. J Biol Chem 266: 17430–17440, 1991.
Doi T, Morita T, Wakabayashi N, Sumi T, Iwai SA, Amekawa S, Sakuda M, Nishimune Y: Induction of instability of p34(cdc2) expression by treatment with cisplatin (CDDP) in mouse teratocarcinoma F9 cells. Cancer Lett 176: 75–80, 2002.
Poggioli GJ, Dermody TS, Tyler KL: Reovirus-induced sigma1s-dependent G2/M phase cell cycle arrest is associated with inhibition of p34(cdc2). J Virol 75: 7429–7434, 2001.
Kanatsu-Shinohara M, Schultz RM, Kopf GS: Acquisition of meiotic competence in mouse oocytes: absolute amounts of p34(cdc2), cyclin B1, cdc25C, and wee1 in meiotically incompetent and competent oocytes. Biol Reprod 63: 1610–1616, 2000.
John S, Workman JL: Bookmarking genes for activation in condensed mitotic chromosomes. Bioessays 20: 275–279, 1998.
Gatter KC, Alcock C, Heryet A, Mason DY: Clinical importance of analysing malignant tumours of uncertain origin with immunohistological techniques. Lancet 1: 1302–1305, 1985.
Morimura T, Kitz K, Budka H: In situ analysis of cell kinetics in human brain tumours. Acta Neuropathol 77: 276–282, 1989.
Robbins BA, de la Vega D, Ogata K, Tan EM, Nakamura RM: Immunohistochemical detection proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 111: 841–845, 1987.
Hoshino T: A commentary on the biology and growth kinetics of low-grade and high-grade gliomas. J Neurosurg 61: 895–900, 1984.
Schlote W, Lang C, Mobius HJ: Growth fraction and growth pattern of neuroectodermal tumors as determined with the monoclonal antibody Ki-67. Abstract, Clin Neuropathol 7: 207, 1988.
Deckert M, Reifenberger G, Wechsler W: Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 115: 179–188, 1989.
Detta A, Hitchcock E: Rapid estimation of the proliferating index of brain tumours. J Neuro-Oncol 8: 245–253, 1990.
Ohno S, Nishi T, Kojima Y, Haraoka J, Ito H, Mizuguchi J: Combined stimulation with interferon and retinoic acid synergistically inhibits proliferation of the glioblastoma cell line GB12. Neurol Res 24: 697–704, 2002.
Wilson CB, Hoshino T, Barker M, Downey R: Kinetics of gliomas in rat and man. Prog Exp Tumor Res 17: 363–372, 1972.
Zatterstrom UK, Kallen A, Wennerberg J: Cell cycle time, growth fraction and cell loss in xenografted head and neck cancer. In Vivo 5: 137–142, 1991.
Stahli C, Staehelin T, Miggiano V, Schmidt J, Haring P: High frequencies of antigen-specific hybridomas: dependence on immunization parameters and prediction by spleen cell analysis. J Immunol Methods 32: 297–304, 1980.
Nishizaki T, Orita T, Saiki M, Furutani Y, Aoki H: Cell kinetics studies of human brain tumours by in vitro labelling using anti-BUdR monoclonal antibody. J Neurosurg 69: 371–374, 1988.
Hoshino T, Nagashima T, Cho KG, Murovic JA, Hodes JE, Wilson CB, Edwards MS, Pitis LH: S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine. Int J Cancer 38: 369–374, 1986.
Murovic JA, Nagashima T, Hoshino T, Edwards MS, Davis RL: Pediatric central nervous system tumors: a cell kinetic study with bromodeoxyuridine. Neurosurgery 19: 900–904, 1986.
Silverman CL, Simpson JR: Cerebellar medulloblastoma: the importance of posterior fossa dose to survival and patterns of failure. Int J Radiat Oncol Biol Phys 8: 1869–1876, 1982.
Goz B: The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. Pharmacol Rev 29: 249–272, 1977.
Gratzner HG: Monoclonal antibody to 5-bromo-and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 218: 474–475, 1982.
Sacchi S, Donelli A, Cocconcelli P, Emilia G, Messerotti A, Piccinini L, Selleri L, Torelli G, Rinaldi G, Torelli U: Monoclonal antibody to 5-bromodeoxyuridine: a sensitive and rapid method for estimating the amount of S-phase cells. In: Biotechnology in Diagnostics (eds. by Koprowsky H, Ferrone S, Albertini A,), pp. 65–70, Elsevier Science Publishers, Amsterdam, 1985.
Assietti R, Butti G, Magrassi L, Danova M, Riccardi A, Gaetani P: Cell-kinetic characteristics of human brain tumors. Oncology 47: 344–351, 1990.
Raza A, Preisler HD, Mayers GL, Bankert R: Rapid enumeration of S-phase cells by means of monoclonal antibodies. New Engl J Med 310: 991, 1984.
Pollack IF, Campbell JW, Hamilton RL, Martinez AJ, Bozik ME: Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer 79: 849–856, 1997.
Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y: Expression of tissue factor in glioma. Noshuyo Byori 13: 115–118, 1996.
Reyes-Mugica M, Rieger-Christ K, Ohgaki H, Ekstrand BC, Helie M, Kleinman G, Yahanda A, Fearon ER, Kleihues P, Reale MA: Loss of DCC expression and glioma progression. Cancer Res 57: 382–386, 1997.
Zurawel RH, Chiappa SA, Allen C, Raffel C: Sporadic medulloblastomas contain oncogenic β-catenin mutations. Cancer Res 58: 896–899, 1998.
Janmaat ML, Giaccone G: Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 8: 576–586, 2003.
Carpenter G, Cohen S: Epidermal growth factor. Ann Rev Biochem 48: 193–216, 1979.
Gregory H: Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature 257: 325–327, 1975.
Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203–212, 1990.
Prigent SA, Lemoine NR: The type I (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 4: 1–24, 1992.
Plowman GD, Culouscou J-M, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M: Ligand-specific activation of HER-4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746–1750, 1993.
Plowman GD, Green JM, Culouscou J-M, Carlton GW, Rothwell VM, Sharon B: Heregulin induces tyrosine phosphorylation of HER-4/p180erbB-4. Nature 366: 473–475, 1993.
Zelada-Hedman M, Werer G, Collins P, Backdahl M, Perez I, Franco S, Jimenez J, Cruz J, Torroella M, Nordenskjold M, Skoog L, Lindblom A: High expression of the EGFR in fibroadenomas compared to breast carcinomas. Anticancer Res 14: 1679–1688, 1994.
Sahin AA: Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol 7: 158–166, 2000.
Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD: Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences. Nature 307: 521–527, 1984.
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452–2467, 1996.
Stoker MGP, Pigott D, Taylor-Papadimitrious J: Response to epidermal growth factor of cultured human mammary epithelial cells from benign tumours. Nature 264: 764–767, 1976.
Coleman S, Silberstein GB, Daniel CW: Ductal morphogenesis in the mouse mammary gland: evidence supporting a role for epidermal growth factor. Dev Biol 127: 304–315, 1988.
Combes RC, Barret-Lee P, Luqmani Y: Growth factor expression in breast tissue. J Steroid Biochem Mol Biol 37: 833–836, 1990.
Derynck R: Transforming growth factor-beta. Cell 54: 593–595, 1988.
Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP: Detection of transforming growth factor-beta in normal, malignant, and hyperproliferative human keratinocytes. J Exp Med 167: 670–675, 1988.
Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ Jr, Ellingsworth L, Derynck R, Voorhees JJ: Overexpression of transforming growth factor β in psoriatic epidermis. Science 243: 811–814, 1989.
Rajkumar T, Gullick WJ: A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines. Br J Cancer 70: 459–465, 1994.
Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, Okuyama T, Hanada K: Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 270: 7495–7500, 1995.
Damjanov I, Mildner B, Knowles BB: Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest 55: 588–592, 1986.
Maguire HC, Green MI: The neu (c-erbB-2) oncogene. Semin Oncol 16: 148–155, 1989.
Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D, Lippman ME: Direct interaction of a ligand for erbB2 oncogene product with the EGF receptor and p185erbB2. Science 249: 1552–1555, 1990.
Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A: Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 78: 267–272, 1996.
Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI: The neuoncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9: 2109–2123, 1994.
Lee K-F, Simon H, Chen H, Bates B, Hung M-C, Hauser C: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394–398, 1995.
Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden Y: Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69: 205–216, 1992.
Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Levy RB: Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69: 559–572, 1992.
Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD: Identification of heregulin, a specific activator of p185erbB2. Science 256: 1205–1210, 1992.
Falls DL, Rosen KM, CorFas G, Lane WS, Fischbach GD: ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell 72: 801–815, 1993.
Marchionni MA, Goodearl AD, Chen MS, Bermingham-McDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kobayashi K: Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362: 312–318, 1993.
Carraway KL III, Sliwkowski MX, Akita R, Platko JV, Gy PM, Naijens A, Diamonti AJ, Vandlen RL, Cantley LC, Cerione RA: The erbB3 gene product is a receptor for heregulin. J Biol Chem 269: 14303–14306, 1994.
Groenen LC, Nice EC, Burgess AW: Structure-function relationships for the EGF/TGF-family of mitogens. Growth Factors 11: 235–257, 1994.
Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193–9197, 1989.
Fisher DA: Epidermal growth factor in the developing mammal. Mead Johnson Symp Perinat Dev Med 32: 33–40, 1988.
Muhlhauser J, Crescimanno C, Kaufmann P, Hofler H, Zaccheo D, Castellucci M: Differentiation and proliferation patterns in human trophoblast revealed by c-erbB-2 oncogene product and EGF-R. J Histochem Cytochem 41: 165–173, 1993.
CorFas G, Rosen KM, Aratake H, Krauss R, Fischbach GD: Differential expression of ARIA isoforms in the rat brain. Neuron 14: 103–115, 1995.
Meyer D, Birchmeier C: Multiple essential functions of neuregulin in development. Nature 378: 386–390, 1995.
Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G: Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378: 390–394, 1995.
Screpanti I, Scarpa S, Meco D, Bellaria D, Stuppia L, Frati L, Modesti A, Gulino A: Epidermal growth factor promotes a neural phenotype in thymic epithelial cells and enhances neuropoietic cytokine expression. J Cell Biol 130: 183–192, 1995.
Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87–98, 1991.
Lofts FJ, Gullick WJ: C-erbB2 amplification and overexpression in human tumors. In: Oncogenes and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer., ed. RB Dickson and ME Lippman. Boston: GenesBoston, Kluwer Academic Publishers. pp. 161–179, 1991.
Salomon DS, Brandt R, Ciardiello F: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183–232, 1995.
Chow NH, Liu HS, Lee EI, Chang CJ, Chan SH, Cheng HL, Tzai TS, Lin JS: Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 17: 1293–1296, 1997.
Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R: EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17: 613–619, 1997.
Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z: Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 20: 320–327, 1998.
Grandis JR, Melhem MF, Barnes EL, Tweardy DJ: Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78: 1284–1292, 1996.
Radinsky R, Risin, Fan, Dong, Bielenberg, Bucana, Fidler: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1: 19–31, 1995.
de Jong JS, van Diest PJ, van der Valk P, Baak JP: Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 184: 53–57, 1998.
Hackel PO, Zwick E, Prenzel N, Ullrich A: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11: 184–189, 1999.
Baselga J, Averbuch SD: ZD1839 (‘Iressa’) as an anticancer agent. Drugs 60 Suppl 1: 33–40; discussion 41–42, 2000.
Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079–5086, 1996.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987.
Varley JM, Swallow JE, Brammar WJ, Wittaker JL, Walker RA: Alterations to either c-erbB2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor shortterm prognosis. Oncogene 1: 423–430, 1987.
Rios MA, Marcias A, Perez R, Lage A, Skoog L: Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res 8: 173–176, 1988.
Tauchi K, Hori S, Osamura RY, Tokuda Y, Tajima T: Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma. Virchows Arch A Pathol Anat Histopathol 416: 65–73, 1989.
Moller P, Mechtersheimer G, Kaufmann M, Moldenhauer G, Momburg F, Mattfeldt T, Otto HF: Expression of epidermal growth factor receptor in benign and malignant primary tumors of the breast. Virchows Archiv A Pathol Anat Histopathol 414: 157–164, 1989.
Parkes HC, Lillicrop K, Howell A, Craig RK: c-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 61: 39–45, 1990.
Goldman R, Ben-Levy R, Peles E, Yarden Y: Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29: 11024–11028, 1990.
Hainsworth PJ, Henderson MA, Stillwell RG, Bennett RC: Comparison of EGF-R, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer. Eur J Surg Oncol 17: 9–15, 1991.
Allred DC, Clark GM, Tandon AK, Molina R, Torney DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: HER2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599–605, 1992.
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castigione M, Collins J, Lindtner J, Senn HJ: Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol 10: 1049–1056, 1992.
Koenders PG, Beex LV, Kienhuis CB, Kloppenborg PW, Benraad TJ: Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 25: 21–27, 1993.
Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA: The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer: a review on 5232 patients. Endocrine Rev 13: 3–17, 1992.
Dittadi R, Donisi PM, Brazzale A, Cappellozza L, Bruscagnin G, Gion M: Epidermal growth factor receptor in breast cancer. Comparison with non-malignant breast tissue. Br J Cancer 67: 7–9, 1993.
Allan SM, Fernando IN, Sandle J, Trott PA: Expression of the c-erbB-2 gene product as detected in cytologic aspirates in breast cancer. Acta Cytol 37: 981–982, 1993.
Jardines L, Weiss M, Fowble B, Greene M: neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 61: 268–282, 1993.
Gramlich TL, Cohen C, Fritsch C, De Rose PB, Gansler T: Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. Am J Clin Pathol 101: 493–499, 1994.
Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH: Cooperative signaling of ErbB-3 and ErbB-2 in neoplastic transformation and human mammary carcinoma cells. Oncogene 10: 1813–1821, 1995.
Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers. Gene 159: 19–27, 1995.
Kreipe H, Feist H, Fischer L, Felgner J, Heidorn K, Mettler L, Parwaresch R: Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53: 1956–1961, 1993.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989.
Quinn CM, Ostrowski JL, Lane SA, Loney DP, Teasdale J, Benson FA: c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 25: 247–252, 1994.
Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Matsumura T: Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. Cancer Lett 95: 79–83, 1995.
Simpson BJ, Weatherill J, Miller EP, Lessells AM, Langdon SP, Miller WR: c-erbB-3 protein expression in ovarian tumours. Br J Cancer 71: 758–762, 1995.
Antoniotti S, Taverna D, Maggiora P, Sapei ML, Hynes NE, De Bortoli M: Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. Br J Cancer 70: 1095–1101, 1994.
Herlyn M: Molecular and cellular basis of melanoma. Austin, KG Landers Co, 1993.
Clark WH Jr, Elder DE, Guerry D, Epstein ME, Greene MH, van Horn M: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15: 1147–1165, 1984.
Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Guerry D 4th, Witmer WK, Thompson J, Matozzo I, Fraser MC: Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med 312: 91–97, 1985.
Bodey B, Kaiser HE, Goldfarb RH: Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. Anticancer Res 16: 517–531, 1996.
Marquardt H, Todaro GJ: Human transforming growth factor. Production by melanoma cell line, purification, and initial characterization. J Biol Chem 257: 5220–5225, 1982.
Delarco JE, Pigott DA, Lazarus JA: Ectopic peptides released by a human melanoma cell line that modulate the transformed phenotype. Proc Natl Acad Sci USA 82: 5015–5019, 1985.
Anisowicz A, Bardwell L, Sager R: Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells. Proc Natl Acad Sci USA 84: 7188–7192, 1987.
Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H: Biology of tumor progression in human melanocytes. Lab Invest 56: 461–474, 1987.
Ellis DL, Nanney LB, King LE Jr: Increased epidermal growth factor receptors in seborrheic keratoses and acrochordons of patients with dysplastic nevus syndrome. J Am Acad Dermatol 23: 1070–1077, 1990.
Bodey B, Bodey B Jr, Groger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 17: 1319–1330, 1997.
Seshadri R, Matthews C, Dobrovic A, Horsfall DJ: The significance of oncogene amplification in primary breast cancer. Int J Cancer 43: 270–273, 1989.
Allred DC, O’Connell P, Fuqua AW: Biomarkers in early breast neoplasia. J Cell Biochem 17G: 125–131, 1993.
Barnes DM: c-erbB-2 amplification in mammary carcinoma. J Cell Biochem 17G: 132–138, 1993.
Symmans WF, Liu J, Knowles DM, Inghirami G: Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 26: 210–216, 1995.
Hiesiger EM, Hayes RL, Pierz DM, Budzilovich GN: Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol 16: 93–104, 1993.
Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC: c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54: 3260–3266, 1994.
Tsugawa K, Fushida S, Yonemura Y: Amplification of the c-erbB-2 gene in gastric carcinoma: correlation with survival. Oncology 50: 418–425, 1993.
Swanson PE, Frierson HF JR, Wick MR: c-erbB-2 (HER2/neu) oncopeptide immunoreactivity in localized, high grade transitional cell carcinoma of the bladder. Mod Pathol 5: 531–536, 1992.
Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW: Expression of the c-erbB-2 (HER2/neu) oncoprotein in human prostatic carcinoma. J Urol 150: 1427–1433, 1993.
Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, Fisher HA: Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 72: 3020–3028, 1993.
Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC Jr: Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164: 15–21, 1991.
Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podartz KC: HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47: 179–185, 1992.
Reinartz JJ, George E, Lindgren BR, Niehans GA: Expression of p53, transforming growth factor β, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 25: 1075–1083, 1994.
Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY: HER2-neu, p53, and DNA analyses as prognostic factors for survival in endometrial carcinoma. Obstet Gynecol 85: 729–734, 1995.
Saffari B, Jones LA, El-Naggar A, Felix JC, George J, Press MF: Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 55: 5693–5698, 1995.
Ro J, El-Naggar A, Ro JY, Blick M, Fraschini F, Fritsche H, Hortobagyi G: c-erbB-2 amplification in node-negative breast cancer. Cancer Res 49: 6941–6944, 1989.
Walker RA, Gullick WJ, Varley JM: An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 60: 426–429, 1989.
Wright C, Angus B, Nicholson S, Sainsbury RC, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CHW: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087–2090, 1989.
Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H: erbB-2 amplification in breast cancer with a high rate of proliferation. Oncogene 60: 137–143, 1991.
Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438, 1991.
Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 oncogene overexpression with high rate of cell proliferation, increased risk for visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650–655, 1991.
Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439–443, 1991.
O’Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63: 444–446, 1991.
Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon DJ, Fourney RM: Correlation between c-erbB-2 amplification and risk of early relapse in node-negative breast cancer. Cancer Res 51: 556–567, 1991.
Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti MA, Testori A: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44–49, 1991.
Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63: 447–450, 1991.
Campani D, Sarnelli R, Fontanini G, Martini L, Cecchetti D, De Luca F, Squartini F: Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer. Ann NY Acad Sci 698: 167–173, 1993.
Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Brandeis J, Paterson MC, Slamon DJ: HER-2/neu expression in node-negative breast cancers: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53: 4960–4970, 1993.
Tsuchiya A, Katagata N, Kimijima I, Abe R: Immunohistochemical overexpression of c-erbB-2 in the prognosis of breast cancer. Surg Today 23: 885–890, 1993.
Horiguchi J, Iino Y, Takei H, Yokoe T, Ishida T, Morishita Y: Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. Oncology 51: 47–51, 1994.
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260–1266, 1994.
Pechoux C, Chardonnet Y, Noel P: Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissues in invasive and non-invasive human breast lesions. Anticancer Res 14: 1343–1360, 1994.
Zschiesche W, Schonborn I, Minguillon C, Spitzer E: Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer. Cancer Lett 81: 89–94, 1994.
Szöllösi J, Balázs M, Feuerstein BG, Benz CC, Waldman FM: ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55: 5400–5407, 1995.
Ali IU, Campbell G, Lidereau R, Callahan R: Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncogene Res 3: 139–146, 1988.
Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58: 448–452, 1988.
Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott C, Ashley S, Monaghan P, Harrison S: c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 58: 453–457, 1988.
Van De Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239–1245, 1988.
Zhou D-J, Ahuja H, Cline MJ: Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105–108, 1989.
Kury F, Sliutz G, Schemper M, Reiner G, Reiner A, Jakesz R, Wrba F, Zeillinger R, Knogler W, Huber J, Holzner H, Spona J: HER-2 oncogene amplification and overals survival of breast carcinoma patients. Eur J Cancer 26: 946–949, 1990.
Richner J, Gerber HA, Locher GW, Goldhirsch A, Gelber RD, Gullick WJ, Berger MS, Groner B, Hynes NE: c-erbB-2 protein expression in node negative breast cancer. Ann Oncol 1: 263–268, 1990.
Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51: 944–948, 1991.
Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771–2777, 1994.
Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC: Expression of erbB3 gene product in breast cancer. Br J Cancer 66: 1116–1121, 1992.
Poller DN, Spendlove I, Baker C, Church R, Ellis IO, Plowman GD, Mayer RJ: Production and characterisation of a polyclonal antibody to the c-erbB3 protein: Examination of c-erbB3 protein expression in adenocarcinomas. J Pathol 168: 275–280, 1992.
Sanidas EE, Filipe MI, Linehan J, Lemoine NR, Gullick WJ, Rajkumar T, Levison DA: Expression of the c-erbB3 gene product in gastric cancer. Int J Cancer 54: 935–940, 1993.
Rajkumar T, Gooden CSR, Lemoine NR, Gullick WJ: Expression of the c-erbB3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. J Pathol 170: 271–278, 1993.
Lemoine NR, Lobresco M, Leung H, Barton C, Hughes CM, Prigent SA, Gullick WJ, Kloppel G: The erbB3 gene in human pancreatic cancer. J Pathol 168: 269–273, 1992.
Arteaga CL: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284: 122–130, 2003.
Gill S, Thomas RR, Goldberg RM: New targeted therapies in gastrointestinal cancers. Curr Treat Options Oncol 4: 393–403, 2003.
Janmaat ML, Giaccone G: The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc) 39 Suppl C: 61–80, 2003.
Batinac T, Gruber F, Lipozencic J, Zamolo-Koncar G, Stasic A, Brajac I: Protein p53—structure, function, and possible therapeutic implications. Acta Dermatovenerol Croat 11: 225–230, 2003.
Demonacos C, La Thangue NB: Drug discovery and the p53 family. Prog Cell Cycle Res 5: 375–382, 2003.
Melino G, Lu X, Gasco M, Crook T, Knight RA: Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 28: 663–670, 2003.
Alarcon RM, Rupnow BA, Graeber TG, Knox SJ, Giaccia AJ: Modulation of c-Myc activity and apoptosis in vivo. Cancer Res 56: 4315–4319, 1996.
Marshall CJ: Tumor suppressor genes. Cell 64: 313–326, 1991.
Bodey B, Bodey B Jr, Siegel SE: Tumor Suppressor Genes in Childhood Malignancies. A Review. Int J Pediatric Hematol/Oncol 6: 47–64, 1998.
Lane DP, Crawford LV: T-antigen is bound to host protein in SV40-transformed cells. Nature 278: 261–263, 1979.
Sarnow P, Ho YS, Williams J, Levine AJ: Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28: 387–394, 1982.
Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76–79, 1990.
Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699–1703, 1991.
Carbon De Fromentel C, Soussi T: TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4: 1–15, 1992.
Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor genes: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878, 1994.
Hollstein M, Sidransky D, Vogelstein B, Harris C: p53 mutations in human cancers. Science 253: 252–254, 1991.
Malkin D, Li FP, Strong LC, Fraumeni JF JR, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233–1238, 1990.
Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747–749, 1990.
Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88: 5413–5417, 1991.
Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA: Constitutional p53 mutations associated with brain tumors in young adults. Genet Cytogenet 82: 106–115, 1995.
Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Molec Carcinogen 15: 1–4, 1996.
Cho MY, Jung SH, Kim TS: p53 protein overexpression in astrocytic neoplasms. Yonsei Med J 36: 521–526, 1995.
Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psych 59: 413–419, 1995.
Kordek R, Biernat W, Alwasiak J, Maculewicz R, Yanagihara R, Liberski PP: p53 protein and epidermal growth factor receptor expression in human astrocytomas. J Neuro-Oncol 26: 11–16, 1995.
Sarkar C, Ralte AM, Sharma MC, Mehta VS: Recurrent astrocytic tumours—a study of p53 immunoreactivity and malignant progression. Br J Neurosurg 16: 335–342, 2002.
Lee CS, Pirdas A, Lee MW: p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis. Australasian J Dermatol 36: 192–195, 1995.
Bergman R, Shemer A, Levy R, Friedman-Birnbaum R, Trau H, Lichtig C: Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions. Amer J Dermatopathol 17: 547–550, 1995.
Sparrow LE, English DR, Heenan PJ, Dawkins HJ, Taran J: Prognostic significance of p53 over-expression in thin melanomas. Melanoma Res 5: 387–392, 1995.
Weiss J, Heine M, Arden KC, Korner B, Pilch H, Herbst RA, Jung EG: Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res 139: 137–154, 1995.
Takahashi T, Nau MM, Chiba T, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491–494, 1989.
Miller CW, Simon K, Aslo A, Kok Y, Yokota J, Buys CHCM, Terada M, Koeffler HP: p53 mutations in human lung tumors. Cancer Res 52: 1695–1698, 1992.
Husgafvel-Pursiainen K, Ridanpaa M, Anttila S, Vainio H: p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J Occupat Environ Med 37: 68–76, 1995.
Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M: Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 56: 72–76, 1996.
Boers JE, Ten Velde GP, Thunnissen FB: p53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Amer J Resp Crit Care Med 153: 411–416, 1996.
Kondo K, Tsuzuki H, Sasa M, Sumimoto M, Uyama T, MondeN Y: The dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 61: 20–26, 1996.
Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Pering RP: Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56: 206–209, 1996.
Goldblum JR, Bartos RE, Carr KA, Frank TS: Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. Am J Surg Pathol 17: 1244–1251, 1993.
Ozturk M: p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338: 1356–1359, 1991.
Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 53: 4691–4694, 1993.
Tabor E: Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 42: 357–365, 1994.
Campbell IG, Eccles DM, Dunn B, Davis M, Leake V: p53 polymorphism in ovarian and breast cancer. Lancet 347: 393–394, 1996.
Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TW, Horne CH: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Brit J Cancer 73: 29–35, 1996.
Callahan R: p53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst 84: 826–827, 1992.
Harris AL: p53 expression in human breast cancer. Adv Cancer Res 59: 69–88, 1992.
Eeles RA, Bartkova J, Lane DP, Bartek J: The role of TP53 in breast cancer development. Cancer Surv 18: 57–75, 1993.
Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32: 39–47, 1994.
Karameris AM, Worthy E, Gorgoulis VG, Quezado M, Anastassiades OT: p53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material. J Pathol 176: 361–372, 1995.
Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 66: 71–141, 1995.
Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093–1096, 1996.
Liu B, Sun D, Xia W, Hung MC, Yu D: Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). J Natl Cancer Inst 89: 1524–1529, 1997.
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Clearly K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705–708, 1989.
Lane DP: p53, guardian of the genome. Nature 358: 15–16, 1992.
Kern S, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B: Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708–1711, 1991.
Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C: Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65: 1083–1091, 1991.
Marx J: New link found between p53 and DNA repair. Science 266: 1321–1322, 1994.
Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D: Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 87: 4766–4770, 1990.
Meek DW, Simon S, Kikkawa U, Eckhart W: The p53 tumor suppressor protein is phosphorylated ar serine 389 by casein kinase II. EMBO J 9: 3253–3260, 1990.
Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G: Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 16: 1126–1137, 1996.
Nikolaev AY, Li M, Puskas N, Qin J, Gu W: PARC: a cytoplasm anchor for p53. Cell 112: 1–2, 2003.
Douc-Rasy S, Benard J: A new view on p53 protein cytoplasmic sequestration. Bull Cancer 90: 380–382, 2003.
Nikolaev AY, Gu W: PARC: a potential target for cancer therapy. Cell Cycle 2: 169–171, 2003.
Fridman JS, Lowe SW: Control of apoptosis by p53. Oncogene 22: 9030–9040, 2003.
SuN Y, Nakamura K, Wendel E, Colburn NH: Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci USA 90: 2827–2831, 1993.
Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17: 493–498, 1997.
Eeles RA, Warren W, Knee G, Bartek J, Averill D, Stratton MR, Blake PR, Tait DM, Lane DP, Easton DF: Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene 8: 1269–1276, 1993.
Nose H, Imazeki F, Ohto M, Omata M: p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer 72: 355–360, 1993.
Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN: Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 53: 2614–2617, 1993.
Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675–679, 1990.
John J, Frech M, Wittinghofer A: Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation. J Biol Chem 263: 11792–11799, 1988.
Mazur M, Glickman BW: Sequence specificity of mutations induced by benzo[a]pyrene-7,8-diol-9,10-epoxide at endogenous aprt gene in CHO cells. Somat Cell Mol Genet 14: 393–400, 1988.
Stüzbecher HW, Chumakov P, Welch WJ, Jenkins JR: Mutant p53 proteins bind hsp 72.73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene 1: 201–211, 1987.
Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531–539, 1988.
von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328–338, 1995.
von Deimling A, Bender B, Jahnke R, Waha A, Kraus J, Albrecht S, Welenreuther R, Faßbender F, Nagel J, Menon AG, Louis DN, Lenartz DD, Schramm J, Wiestler OD: Loci associated with malignant progression in astrocytomas: A candidate on chromosome 19q. Cancer Res 54: 1397–1401, 1994.
Fults D, Petronio J, Noblett BD, Pedone CA: Chromosome 11p15 deletions in human malignant astrocytomas and primitive neuroectodermal tumors. Genomics 14: 799–801, 1992.
James CD, Carlblom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK: Clonal genomic alterations in glioma malignancy stages. Cancer Res 48: 5546–5551, 1988.
James CD, He J, Carlblom E, Nordenskjold M, Cavenee WK, Collins VP: Chromosome 9 deletion mapping reveals interferon and interferon-1 gene deletions in human glial tumors. Cancer Res 51: 1684–1688, 1991.
Olopade OI, Buchhagen DL, Malik K, Sherman J, Nobori T, Bader S, Nau MM, Gazdar AF, Minna JD, Diaz MO: Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 53: 2410–2415, 1993.
Ransom DT, Ritland SR, Kimmel DW, Moertel CA, Dahl RJ, Scheithauer BW, Kelly PJ, Jenkins BR: Cytogenetic and loss of heterozygosity studies in ependymoma, pilocytic astrocytoma and oligodendrogliomas. Genes Chromosom Cancer 5: 348–356, 1992.
Venter DJ, Bevan KL, Ludwig RL, Riley TEW, Jat PS, Thomas DGT, Noble MD: Retinoblastoma gene deletions in human glioblastomas. Oncogene 6: 445–448, 1991.
von Deimling A, Eibl RH, Ohgaki H, Louis DN, von Ammon K, Petersen I, Kleihues P, Chung RY, Wiestler OD, Seizinger BR: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52: 2987–2990, 1992.
Liu T, Yan H, Kuismanen S, Percesepe A, Bisgaard ML, Pedroni M, Benatti P, Kinzler KW, Vogelstein B, Ponz de Leon M, Peltomaki P, Lindblom A: The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. Cancer Res 61: 7798–7802, 2001.
Trojan J, Zeuzem S, Randolph A, Hemmerle C, Brieger A, Raedle J, Plotz G, Jiricny J, Marra G: Functional Analysis of hMLH1 Variants and HNPCC-Related Mutations Using a Human Expression System. Gastroenterology 122: 211–219, 2002.
Deng G, Chen A, Pong E, Kim YS: Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene 20: 7120–7127, 2001.
Muller-Koch Y, Kopp R, Lohse P, Baretton G, Stoetzer A, Aust D, Daum J, Kerker B, Gross M, Dietmeier W, Holinski-Feder E: Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a cohort of 254 suspected HNPCC (hereditary nonpolyposis colorectal cancer) patients: mutations or polymorphisms? Eur J Med Res 6: 473–482, 2001.
Shin KH, Shin JH, Kim JH, Park JG: Mutational Analysis of Promoters of Mismatch Repair Genes hMSH2 and hMLH1 in Hereditary Nonpolyposis Colorectal Cancer and Early Onset Colorectal Cancer Patients: Identification of Three Novel Germ-line Mutations in Promoter of the hMSH2 Gene. Cancer Res 62: 38–42, 2002.
Hussein MR, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, Sudilovsky O: Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas. Am J Dermatopathol 23: 308–314, 2001.
Yeh CC, Lee C, Dahiya R: DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem Biophys Res Commun 285: 409–413, 2001.
Chung TK, Cheung TH, Wang VW, Yu MY, Wong YF: Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinico-pathological association. Gynecol Obstet Invest 52: 98–103, 2001.
Peiro G, Diebold J, Mayr D, Baretton GB, Kimmig R, Schmidt M, Lohrs U: Prognostic relevance of hMLH1, hMSH2, and BAX protein expression in endometrial carcinoma. Mod Pathol 14: 777–783, 2001.
Aubry MC, Halling KC, Myers JL, Tazelaar HD, Yang P, Thibodeau SN: DNA mismatch repair genes hMLH1, hMSH2, and hMSH6 are not inactivated in bronchioloalveolar carcinomas of the lung. Cancer 92: 2898–2901, 2001.
Wang L, Bani-Hani A, Montoya DP, Roche PC, Thibodeau SN, Burgart LJ, Roberts LR: hMLH1 and hMSH2 expression in human hepatocellular carcinoma. Int J Oncol 19: 567–570, 2001.
Derradji H, Baatout S: Apoptosis: a mechanism of cell suicide. In Vivo 17: 185–192, 2003.
Xerri L, Devilard E, Ayello C, Brousset P, Reed JC, Emile JF, Hassoun J, Parmentier S, Birg F: Cysteine protease CPP32, but not Ich1-L, is expressed in germinal center B cells and their neoplastic counterparts. Hum Pathol 28: 912–921, 1997.
Srinivasan A, Roth KA, Sayers RO, Shindler KS, Wong AM, Fritz LC, Tomaselli KJ: In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system. Cell Death Differ 5: 1004–1016, 1998.
Kopper L: Apoptozis es a daganatok. Magyar Onkologia 47: 123–131, 2003.
Ockner RK: Apoptosis and liver diseases: recent concepts of mechanism and significance. J Gastroenterol Hepatol 16: 248–260, 2001.
Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239–257, 1972.
Kuan CY, Roth KA, Flavell RA, Rakic P: Mechanisms of programmed cell death in the developing brain. Trends Neurosci 23: 291–297, 2000.
Arends MJ, Wyllie AH: Apoptosis: Mechanisms and roles in pathology. Int Rev Exp Pathol 32: 223–254, 1991.
Patel T, Gores GJ, Kaufmann SH: The role of proteases during apoptosis. FASEB J 10: 587–597, 1996.
Ellis RE, Jacobson DM, Horvitz HR: Genes required for the engulfment of cell corpses during programmed cell death in Caenorhabditis elegans. Genetics 129: 79–94, 1991.
Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR: The C. elegans death gene ced-3 encodes a protein similar to mammalian interleukin-1 β-converting enzyme. Cell 75: 641–652, 1993.
Hengartner MO Horvitz HR: C. elegans cell survival gene ced-9 encodes a functional homologue of the mammalian protooncogene bcl-2. Cell 76: 665–676, 1994.
Wang S, El-Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628–8633, 2003.
Mischak R: Assessment of caspase activity: synthetic substrates and inhibitors. Bioconcepts, 9.2: 1–20, 2003.
Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW: A combinatorial approach defines specificities of members of the caspase family and granzyme B. J Biol Chem 272: 17907–17911, 1997.
Chang HY, Yang X: Proteases for cell suicide: Function and regulation of caspases. Mol Biol Rev 64: 821–846, 2000.
Earnshaw WC, Martins LM, Kaufmann SH: Mammalian caspases: structure, activation, substrates and functions during apoptosis. Ann Rev Biochem 68: 383–424, 1999.
Hengartner MO: The biochemistry of apoptosis. Nature 407: 769–776, 2000.
Kohler C, Orrenius S, Zhivotvsky B: Evaluation of caspase activity in apoptotic cells. J Immunol Methods 265: 97–110, 2002.
Ravagnan L, Roumier T, Kroemer G: Mitochondria, the killer organelles and their weapons. J Cell Physiol 192: 131–137, 2002.
Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147–157, 1996.
Jia L, Patwari Y, Kelsey SM, Srinivasula SM, Agrawal SG, Alnemri ES, Newland AC: Role of Smac in human leukaemic cell apoptosis and proliferation. Oncogene 22: 1589–1599, 2003.
Stennicke HR, Salvesen GS: Biochemical characteristics of caspases-3,-6,-7 and-8. J Biol Chem 272: 25719–25723, 1997.
Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y: Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J 16: 2271–2281, 1997.
Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, Yamamoto K, Sasada M: Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 187: 587–600, 1998.
Srinivasula SM, Ahmad M, MacFarlane M, Luo Z, Huang Z, Fernandes-Alnemri T, Alnemri ES: Generation of constitutively active recombinant caspases-3 and-6 by rearrangement of their subunits. J Biol Chem 273: 10107–10111, 1998.
Kang JJ, Schaber MD, Srinivasula SM, Alnemri ES, Litwack G, Hall DJ, Bjornsti MA: Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae. J Biol Chem 274: 3189–3198, 1999.
Fernandes-Alnemri T, Litwack G, Alnemri ES: Mch 2, a new member of the apoptotic Ced-3/Ice cysteine protease gene family. Cancer Res 55: 2737–2742, 1995.
Fernandes-Alnemri T, Armstrong RC, Krebs J, Srinivasula SH, Wang L, Bullrich F, Fritz LC, Trapani JA, Tomaselli KJ, Litwack G, Alnemri ES: In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci USA 93: 7464–7469, 1996.
Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ: Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8 and-10 in a caspase-9-dependent manner. J Cell Biol 144: 281–292, 1999.
Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES: Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc Natl Acad Sci USA 93: 14486–14491, 1996.
Peter ME, Kischkel FC, Scheuerpflug CG, Medema JP, Debatin KM, Krammer PH: Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur J Immunol 27: 1207–1212, 1997.
Perera LP, Waldmann TA: Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE. Proc Natl Acad Sci USA 95: 14308–14313, 1998.
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680–1683, 1998.
Skulachev VP: Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett 423: 275–280, 1998.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479–489, 1997.
Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, Elia A, de la Pompa JL, Kagi D, Khoo W, Potter J, Yoshida R, Kaufman SA, Lowe SW, Penninger JM, Mak TW: Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94: 339–352, 1998.
Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES: Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1: 949–957, 1998.
Nakagawara A, Nakamura Y, Ikeda H, Hiwasa T, Kuida K, Su MS, Zhao H, Cnaan A, Sakiyama S: High levels of expression and nuclear localization of interleukin-1 β converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res. 57: 4578–4584, 1997.
Ray SK, Patel SJ, Welsh CT, Wilford GG, Hogan EL, Banik NL: Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. J Neurosci Res 69: 197–206, 2002.
Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, Debatin K-M, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301–305, 1989.
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233–243, 1991.
Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR: Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257: 212–214, 1992.
Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119–128, 1992.
Korsmeyer SJ: Bcl-2: a repressor of lymphocyte death. Immunol Today 13: 285–288, 1992.
Itoh N, Nagata S: A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 268: 10932–10937, 1993.
Hoffman B, Liebermann DA: Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators. Oncogene 9: 1807–1812, 1994.
Ehl S, Hoffmann-Rohrer U, Nagata S, Hengartner H, Zinkernagel R: Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J Immunol 156: 2357–2360, 1996.
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Fas (APO-1, CD95) receptor expression and new options of immunotherapy in childhood medulloblastomas. Anticancer Res 19: 3293–3314, 1999.
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Fas (APO-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells? In Vivo 13: 357–373, 1999.
Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 68: 421–427, 1992.
Calderhead DM, Buhlmann JE, van den Eertwegh AJM, Claassen E, Noelle RJ, Fell HP: Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol 151: 5261–5271, 1993.
Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76: 959–962, 1994.
Nagata S: Fas and Fas ligand: a death factor and its receptor. Adv Immunol 57: 129–144, 1994.
Ogasawara J, Suda T, Nagata S: Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody. J Exp Med 181: 485–491, 1995.
Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, Ramsdell F, Lynch DH: Fas transduces activation signals in normal human T lymphocytes. J Exp Med 178: 2231–2235, 1993.
Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747–1756, 1989.
Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364: 806–809, 1993.
Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 75: 1169–1178, 1993.
Suda T, Nagata S: Purification and characterization of the Fas ligand that induces apoptosis. J Exp Med 179: 873–878, 1994.
Nagata S, Golstein P: The Fas death factor. Science 267: 1449–1456, 1995.
Schulze-Osthoff K: The Fas/APO-1 receptor and its deadly ligand. Trends Cell Biol 4: 421–426, 1995.
Cohen PL, Eisenberg RA: Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9: 243–269, 1991.
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314–317, 1992.
Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969–976, 1994.
Zhou T, Bluethmann H, Eldridge J, Berry K, Mountz JD: Abnormal thymocyte development and production of autoreactive T cells in TCR transgenic autoimmune mice. J Immunol 147: 466–474, 1991.
Zhou T, Mountz JD, Edwards III CK, Berry K, Bluethmann H: Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mouse. J Exp Med 176: 1063–1072, 1992.
Zhou T, Bluethmann H, Eldridge J, Berry K, Mountz JD: Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor β transgenic mouse. J Immunol 150: 3651–3667, 1993.
Owen-Schaub LB, Yonehara S, Crump WL III, Grimm E: DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 140: 197–205, 1992.
Klas C, Debatin K-M, Jonker RR, Krammer PH: Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 5: 625–630, 1993.
Su X, Zhou T, Wu J, Jope R, Mountz JD: Dephosphorylation of a 65kD protein associated with signaling for Fas-mediated apoptosis. (Abstract) FASEB J 8: A218, 1994.
Mountz JD, Zhou T, Wu J, Wang W, Su X, Cheng J: Regulation of apoptosis in immune cells. J Clin Immunol 15: 1–16, 1995.
Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 55: 5528–5530, 1995.
Tachibana O, Lampe J, Kleihues P, Ohgaki H: Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 92: 431–434, 1996.
Dietrich P-Y, Walker PR, Saas P, de Tribolet N: Immunobiology of gliomas: new perspectives for therapy. In: Challenges and opportunities in pediatric oncology (Holmes FF, Kepes JJ, Vats TS, Schuler D, Nyary I, eds). New York, Ann NY Acad Sci 824:124–140, 1997.
Cohen JJ: Apoptosis. Immunol Today 14: 126–130, 1993.
Strater J, Wellisch I, Riedl S, Walczak H, Koretz K, Tandara A, Krammer PH, Moller P: CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 113: 160–167, 1997.
Reyher von U, Strater J, Kittstein W, Gschwendt M, Krammer PH, Moller P: Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58: 526–534, 1998.
Weller M, Schuster M, Pietsch T, Schabet M: CD95 ligand-induced apoptosis of human medulloblastoma cells. Cancer Lett 128: 121–126, 1998.
Schiffer D, Cavalla P, Chio A, Giordana MT, Marino S, Mauro A, Migheli A: Tumor cell proliferation and apoptosis in medulloblastoma. Acta Neuropathol 87: 362–370, 1994.
Schubert TE, Cervos-Navarro J: The histopathological and clinical relevance of apoptotic cell death in medulloblastomas. J Neuropathol Exp Neurol 57: 10–15, 1998.
Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34(4 Suppl 5): 9–19, 1997.
Basu A, Haldar S: Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 13: 659–664, 1998.
Hockenbery DM: The bcl-2 oncogene and apoptosis. Semin Immunol 4: 413–420, 1992.
Vile GF, Tyrrell RM: Oxidative stress resulting from ultraviolet A irradiation of human skin fibroblasts leads to a heme oxygenase-dependent increase in ferritin. J Biol Chem 268: 14678–14681, 1993.
Haldar S, Jena N, Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507–4511, 1995.
Haldar S, Chintapalli J, Croce CM: Taxol-induced bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253–1255, 1996.
Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 signal transduction pathway. Cancer Res 56: 1851–1854, 1996.
Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 355: 440–442, 1988.
Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334–336, 1990.
Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241–251, 1993.
Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870–5878, 1989.
Martin SJ, Lennon SV, Bonham AM, Cotter TG: Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 145: 1859–1867, 1990.
Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353–2362, 1990.
Perotti M, Toddei F, Mirabelli F, Vairetti M, Bellomo G, McConkey DJ, Orrenius S: Calcium-dependent DNA fragmentation in human synovial cells exposed to cold shock. FEBS Lett 259: 331–334, 1990.
Kruman II, Matylevich NP, Beletsky IP, Afanasyev VN, Umansky SR: Apoptosis of murine BW 5147 thymoma cells induced by dexamethasone and gamma-irradiation. J Cell Physiol 148: 267–273, 1991.
Martin SJ, Cotter TG: Ultraviolet B irradiation of human leukaemia HL-60 cells in vitro induces apoptosis. Int J Radiat Biol 59: 1001–1016, 1991.
Del Bino G, Lassota P, Darzynkiewicz Z: The S-phase cytotoxicity of camptothecin. Exp Cell Res 193: 27–35, 1991.
Del Bino G, Darzynkiewicz Z: Camptothecin, teniposide, or 4′-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells. Cancer Res 51: 1165–1169, 1991.
Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y: Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 51: 6280–6285, 1991.
O’Connor PM, Wassermann K, Sarang M, Magrath I, Bohr VA, Kohn KW: Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt’s lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res 51: 6550–6557, 1991.
Hara A, Hirose Y, Yoshimi N, Tanaka T, Mori H: Expression of Bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors. Neurol Res 19: 623–628, 1997.
Yew DT, Wang HH, Zheng DR: Apoptosis in astrocytomas with different grades of malignancy. Acta Neurochir 140: 341–347, 1998.
Schiffer D, Cavalla P, Migheli A, Chio A, Giordana MT, Marino S, Attanasis A: Apoptosis and cell proliferation in human neuroepithelial tumours. Neurosci Lett 195: 81–84, 1995.
Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L: Bcl-2 distribution in neuroepithelial tumours: an immunohistochemical study. J Neurooncol 27: 101–109, 1996.
Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H: Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7: 863–869, 1997.
Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, Kleihues P, Ohgaki H: Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 57: 239–245, 1998.
Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC: Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150: 805–814, 1997.
Altieri DC, Marchisio PC, Marchisio C: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79: 1327–1333, 1999.
Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917–921, 1997.
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580–584, 1998.
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247–3257, 2002.
Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1: 461–466, 1999.
Deveraux QL, Reed JC: IAP family proteins—suppressors of apoptosis. Genes Dev 13: 239–252, 1999.
Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O, Margolis RL: Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual α-helical extensions. Mol Cell 6: 183–189, 2000.
Miller LK: An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol 9: 323–328, 1999.
Sun C, Cai M, Gunasekera AH, Meadows RP, Wang H, Chen J, Zhang H, Wu W, Xu N, Ng SC, Fesik SW: NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 401: 818–822, 1999.
Shi Y: Survivin structure: crystal unclear. Nat Struct Biol 7: 620–623, 2000.
O’Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC: Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97: 13103–13107, 2000.
Ambrosini G, Adida C, Sirugo G, Altieri DC: Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273: 11177–11182, 1998.
Conway EM, Pollefeyt S, Steiner-Mosonyi M, Luo W, Devriese A, Lupu F, Bono F, Leducq N, Dol F, Schaeffer P, Collen D, Herbert JM: Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 123: 619–631, 2002.
Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M, Akahane K, Shiraki K: Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 19: 3225–3234, 2000.
Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry 40: 1117–1123, 2001.
Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T: Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA 96: 1457–1462, 1999.
Katoh M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G, Dietrich PY: Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol 64: 71–76, 2003.
Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K: Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97: 1077–1083, 2003.
Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440–1443, 1985.
Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152: 43–49, 1998.
Lu CD, Altieri DC, Tanigawa N: Expression of a novel anti-apoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58: 1808–1812, 1998.
Rabbani SA: Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 12: 135–142, 1998.
Czubayko F, Liadet-Coopman EDE, Aigner A, Tuveson AT, Berchem GJ, Wellstein A: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Med 3: 1137–1140, 1997.
Rak J, Kerbel RS: bFGF and tumor angiogenesis—back in the limelight? Nature Med 3: 1083–1084, 1997.
Czubayko F, Smith RV, Chung HC, Wellstein A: Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 269: 28243–28248, 1994.
Morrison RS, Giordano S, Yamaguchi F, Hendrickson S, Berger MS, Palczewski K: Basic fibroblast growth factor expression is required for clonogenic growth of human glioma cells. J Neurosci Res 34: 502–509, 1993.
Redekop GJ, Naus CC: Transfection of bFGF sense and antisense cDNA resulting in modification of malignant glioma growth. J Neurosurg 82: 83–90, 1995.
Stiles JD, Ostrow PT, Balos LL, Greenberg SJ, Plunkett R, Grand W, Heffner RR Jr: Correlation of endothelin-1 and transforming growth factor β 1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 56: 435–439, 1997.
Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361–8364, 1990.
Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J: Structure and expression of the membrane proteoglycan β-glycan, a component of the TGF-β receptor system. Cell 67: 785–795, 1991.
Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M: Expression and structural features of endoglin (CD105), a transforming growth factor β1 and β3 binding protein, in human melanoma. Br J Cancer 74: 1586–1591, 1996.
Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdzar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res 1: 1623–1634, 1995.
Kumar P, Wang JM, Bernabeu C: CD 105 and angiogenesis. J Pathol 178: 363–366, 1996.
Fernandez-Ruiz E, St-Jacques S, Bellon T, Letarte M, Bernabeu C: Assignment of the human endoglin gene (END) to 9q34 qter. Cytogenet Cell Genet 64: 204–207, 1993.
Wang JM, Kumar S, van Agthoven A, Kumar P, Pye D, Hunter RD: Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Int J Cancer 62: 791–796, 1995.
Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, Funa K: Enhanced expression of transforming growth factor-β and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62: 386–392, 1995.
Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K: Expression and prognostic significance of TGF-β isotypes, latent TGF-β 1 binding protein, TGF-β type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 73: 213–220, 1995.
Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ, Rayan G, Koch AE: Increased synovial expression of transforming growth factor (TGF)β receptor endoglin and TGF-β1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 76: 187–194, 1995.
Zhang H, Shaw AR, Mak A, Letarte M: Endoglin is a component of the transforming growth factor (TGF)β receptor complex of human pre-B leukemic cells. J Immunol 156: 564–573, 1996.
Griffioen AW, Damen CA, Blijham GH, Groenewegen G: Endoglin/CD 105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Treat 39: 239–242, 1996.
Shovlin CL, Scott J: Inherited diseases of the vasculature. Annu Rev Physiol 58: 483–507, 1996.
Pichuantes S, Vera S, Bourdeau A, Pece N, Kumar S, Wayner EA, Letarte M: Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens 50: 265–276, 1997.
Zagzag D: Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol 146: 293–309, 1995.
Bouck N: Angiogenesis: a mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis. Cancer Treat Res 63: 359–371, 1992.
Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56: 2185–2190, 1996.
Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP: Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 29: 910–914, 1998.
Sharkey AM, Charnock-Jones DS, Boocock CA, Brown KD, Smith SK: Expression of mRNA for vascular endothelial growth factor in human placenta. J Reprod Fertil 99: 609–615, 1993.
Aase K, Lymboussaki A, Kaipainen A, Olofsson B, Alitalo K, Eriksson U: Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. Dev Dyn 215: 12–25, 1999.
Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M: Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55: 1189–1193, 1995.
Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH: Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91: 153–159, 1993.
Morii K, Tanaka R, Washiyama K, Kumanishi T, Kuwano R: Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 194: 749–755, 1993.
Wizigmann-Voos S, Breier G, Risau W, Plate KH: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358–1364, 1995.
Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520–529, 1994.
Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF, Dietrich PY, Regli L, Janzer RC, Bucher P, Stupp R, de Tribolet N, Domany E, Hegi ME: Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63: 6613–6625, 2003.
Breier G, Albrecht U, Sterrer S, Risau W: Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114: 521–532, 1992.
Risau W: Embryonic angiogenesis factors. Pharmacol Ther 51: 371–376, 1991.
Risau W: Molecular biology of blood-brain barrier ontogenesis and function. Acta Neurochir (Wien) [Suppl] 60: 109–112, 1994.
Shim JW, Koh YC, Ahn HK, Park YE, Hwang DY, Chi JG: Expression of bFGF and VEGF in brain astrocytoma. J Korean Med Sci 11: 149–157, 1996.
Melnyk O, Shuman MA, Kim KJ: Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56: 921–924, 1996.
Machein MR, Kullmer J, Fiebich BL, Plate KH, Warnke PC: Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 44: 732–740, 1999. discussion 740–741.
Liotta LA, Abe S, Robey PG, Martin GR: Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci USA 76: 2268–2272, 1979.
Seltzer JL, Adams SA, Grant GA, Eisen AZ: Purification and properties of a gelatin-specific neutral protease from human skin. J Biol Chem 256: 4662–4668, 1981.
Seltzer JL, Eisen AZ, Bauer EA, Morris NP, Glanville RW, Burgeson RE: Cleavage of type VII collagen by interstitial collagenase and type IV collagenase (gelatinase) derived from human skin. J Biol Chem 264: 3822–3826, 1989.
Seltzer JL, Akers KT, Weingarten H, Grant GA, McCourt DW, Eisen AZ: Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. J Biol Chem 265: 20409–20413, 1990.
Gadher SJ, Schmid TM, Heck LW, Woolley DE: Cleavage of collagen type X by human synovial collagenase and neutrophil elastase. Matrix 9: 109–115, 1989.
Welgus HG, Fliszar CJ, Seltzer JL, Schmid TM, Jeffrey JJ: Differential susceptibility of type X collagen to cleavage by two mammalian interstitial collagenases and 72-kDa type IV collagenase. J Biol Chem 265: 13521–13527, 1990.
Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG: Human 92-and 72-kilodalton type IV collagenases are elastases. J Biol Chem 266: 7870–7875, 1991.
Hibbs MS, Hoidal JR, Kang AH: Expression of a metalloproteinase that degrades native type V collagen and denatured collagens by cultured human alveolar macrophages. J Clin Invest 80: 1644–1650, 1987.
Niyibizi C, Chan R, Wu JJ, Eyre D: A 92 kDa gelatinase (MMP-9) cleavage site in native type V collagen. Biochem Biophys Res Commun 202: 328–333, 1994.
Pourmotabbed T: Relation between substrate specificity and domain structure of 92-kDa type IV collagenase. Ann NY Acad Sci 732: 372–374, 1994.
Pourmotabbed T, Solomon TL, Hasty KA, Mainardi CL: Characteristics of 92 kDa type IV collagenase/gelatinase produced by granulocytic leukemia cells: structure, expression of cDNA in E. coli and enzymic properties. Biochim Biophys Acta 1204: 97–107, 1994.
Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA: The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 267: 19470–19474, 1992.
Nguyen Q, Murphy G, Hughes CE, Mort JS, Roughley PJ: Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein. Biochem J 295: 595–598, 1993.
Okada Y, Nagase H, Harris ED Jr: A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem 261: 14245–14255, 1986.
Muller D, Quantin B, Gesnel MC, Millon-Collard R, Abecassis J, Breathnach R: The collagenase gene family in humans consists of at least four members. Biochem J 253: 187–192, 1988.
Flannery CR, Lark MW, Sandy JD: Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem 267: 1008–1014, 1992.
Nguyen Q, Murphy G, Roughley PJ, Mort JS: Degradation of proteoglycan aggregate by a cartilage mettaloproteinase. Evidence for the involvement of stromelysin in the degradation of link protein heterogeneity in situ. Biochem J 259: 61–67, 1989.
Wu JJ, Lark MW, Chun LE, Eyre DR: Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J Biol Chem 266: 5625–5628, 1991.
Mott JD, Khalifah RG, Nagase H, Shield CF 3rd, Hudson JK, Hudson BG: Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 52: 1302–1312, 1997.
Wilhelm SM, Shao ZH, Housley TJ, Seperack PK, Baumann AP, Gunja-Smith Z, Woessner JF jr: Matrix metalloproteinase-3 (stromelysin-1). Identification as the cartilage acid metalloprotease and effect of pH on catalytic properties and calcium affinity. J Biol Chem 268: 21906–21913, 1993.
Enghild JJ, Salvesen G, Brew K, Nagase H: Interaction of human rheumatoid synovial collagenase (matrix metalloproteinase 1) and stromelysin (matrix metalloproteinase 3) with human a α2-macroglobulin and chicken ovostatin. Binding kinetics and identification of matrix metalloproteinase cleavage sites. J Biol Chem 264: 8779–8785, 1989.
Mast AE, Enghild JJ, Nagase H, Suzuki K, Pizzo SV, Salvesen G: Kinetics and physiologic relevance of the inactivation of α 1-proteinase inhibitor, α 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase),-2 (72-kDa gelatinase/type IV collagenase), and-3 (stromelysin). J Biol Chem 266: 15810–15816, 1991.
Harrison R, Teahan J, Stein R: A semicontinuous, high-performance liquid chromatography-based assay for stromelysin. Annals Biochem 180: 100–113, 1989.
Fowlkes JL, Enghild JJ, Susuki K, Nagase H: Matrix metalloproteinasees degrade insulin-like growth factor-binding protein-1 in dermal fibroblast cultures. J Biol Chem 269: 25742–25746, 1994.
Mayer U, Mann K, Timpl R, Murphy G: Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodeling. Eur J Biochem 217: 877–884, 1993.
Sasaki T, Gohring W, Mann K, Maurer P, Hohenester E, Knauper V, Murphy G, Timpl R: Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J Biol Chem 272: 9237–9243, 1997.
Sasaki T, Mann K, Murphy G, Chu ML, Timpl: Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases. Eur Biochem 240: 427–434, 1996.
Bini A, Itoh Y, Kudryk BJ, Nagase H: Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): Hydrolysis of the γGly404-Ala405 peptide bond. Biochem 35: 13056–13063, 1996.
Imai K, Shikata H, Okada Y: Degradation of vitronectin by matrix metalloproteinases-1,-2,-3,-7, and-9. FEBS Lett 369: 249–251, 1995.
Knauper V, Wilhelm SM, Seperack PK, DeClerck YA, Langley KE, Osthues A, Tschesche H: Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 295: 581–586, 1993.
Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G: Biochemical characterization of human collagenase-3. J Biol Chem 235: 187–191, 1996.
Nagase H, Enghild JJ, Suzuki K, Salvesen G: Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and 4-aminophenyl) mercuric acetate. Biochemistry. 29: 5783–5789, 1990.
Ogata Y, Enghild JJ, Nagase H: Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 267: 3581–3584, 1992.
Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H: Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 29: 10261–10270, 1990.
Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, Lopez-Otin C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269: 16766–16773, 1994.
Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G: Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 271: 17124–17131, 1996.
Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J, Van Wart H, Poole AR: Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 99: 1534–1545, 1997.
Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE: Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 97: 761–768, 1996.
Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B: Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 153: 429–437, 1998.
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Matrix metalloproteinase expression in childhood medulloblastomas/primitive neuroectodermal tumors. In Vivo 14: 667–673, 2000.
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Matrix metalloproteinase expression in childhood astrocytomas. Anticancer Res 20: 3287–3292, 2000.
Rooprai HK, McCormick D: Proteases and their inhibitors in human brain tumours: a review. Anticancer Res 17: 4151–4162, 1997.
Rooprai HK, Van Meter T, Rucklidge GJ, Hudson L, Everall IP, Pilkington GJ: Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours. Int J Oncol 13: 1153–1157, 1998.
Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y: Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 81: 69–77, 1994.
Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 83: 298–307, 1995.
Nakagawa T, Kubota T, Kabuto M, Fujimoto N, Okada Y: Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase=gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix. J Neurooncol 28: 13–24, 1996.
Sawaya RE, Yamamoto M, Gokaslan ZL, Wang SW, Mohanam S, Fuller GN, McCutcheon IE, Stetler-Stevenson WG, Nicolson GL, Rao JS: Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 14: 35–42, 1996.
Rao JS, Yamamoto M, Mohaman S, Gokaslan ZL, Fuller GN, Stetler-Stevenson WG, Rao VH, Liotta LA, Nicolson GL, Sawaya RE: Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 14: 12–18, 1996.
Vince GH, Wagner S, Pietsch T, Klein R, Goldbrunner RH, Roosen K, Tonn JC: Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas. Int J Dev Neurosci 17: 437–445, 1999.
Janckila AJ, Yam LT, Li C-Y: Immunoalkaline phosphatase cytochemistry. Amer J Clin Pathol 84: 476–480, 1985.
Zeltzer PM, Bodey B, Marlin A, Kemshead J: Immunophenotype profile of childhood medulloblastomas and supratentorial primitive neuroectodermal tumors using 16 monoclonal antibodies. Cancer 66: 273–283, 1990.
Yam LT, Janckila AJ, Epremian BE, Li C-Y: Diagnostic significance of levamisole-resistant alkaline phosphatase in cytochemistry and immunocytochemistry. Amer J Clin Pathol 91: 31–36, 1989.
Strasburger CJ, Amir-Zaltsman Y, Kohen F: The avidin-biotin reaction as an universal amplification system in immunoassays. Prog Clin Biol Res 285: 79–100, 1988.
Wilchek M, Bayer EA: Introduction to avidin-biotin technology. Methods Enzymol 184: 5–13, 1990.
Duhamel RC, Whitehead JS: Prevention of nonspecific binding of avidin. Methods Enzymol 184: 201–207, 1990.
Diamandis EP, Christopoulos TK: The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 37: 625–636, 1991.
Bodey B: Cancer-Testis antigens: promising targets for antigen directed anti-neoplastic immunotherapy. EOBT 2: 577–584, 2002.
Bodey B: Genetically engineered antibodies for direct anti-neoplastic treatment and neoplastic cells directed delivery of various therapeutic agents. EOBT 1: 603–617, 2001.
Ma Z, Khatlani TS, Li L Sasaki K, Okuda M, Inokuma H, Onishi T: Molecular cloning and expression analysis of feline melanoma antigen (MAGE) obtained from a lymphoma cell line. Vet Immunol Immunopathol 83: 241–252, 2001.
Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, Nguyen DM, Schrump DS: Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 71: 295–301; discussion 301–302, 2001.
Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S: An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61: 5544–5551, 2001.
Ohman Forslund K, Nordqvist K: The melanoma antigen genes—any clues to their functions in normal tissues? Exp Cell Res 265: 185–194, 2001.
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647, 1991.
De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, et al.: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40: 360–369, 1994.
Rogner UC, Wilke K, Steck E, Korn B, Poutska A: The melanoma antigen (MAGE) family is clustered in the chromosomal band Xq28. Genomics 29: 725–731, 1995.
Lurquin C, De Smet C, Brasseur F, Muscatelli F, Martelange V, De Plaen E, Brasseur R, Monaco AP, Boon T: Two members of th human MAGEB gene family loacted in Xp21.3 are expressed in tumors of various histological origins. Genomics 46: 397–408, 1997.
Lucas S, De Smet C, Arden KC, Viars CS, Lethe B, Lurquin C, Boon T: Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 58: 743–752, 1998.
Pold M, Zhou J, Chen GL, Hall JM, Vescio RA, Berenson JR: Identification of a new, unorthodox member of the MAGE gene family. Genomics 59: 161–167, 1999.
Aubry F, Satie AP, Rioux-Leclercq N, Rajpert-De Meyts E, Spagnoli GC, Chomez P, De Backer O, Jegou B, Samson M: MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer 92: 2778–2785, 2001.
Gillespie AM, Coleman RE: The potential of melanoma antigen expression in cancer therapy. Cancer Treat Rev 25: 219–227, 1999.
Chen Y-T, Old LJ: Cancer-testis antigens: targets for cancer immunotherapy. Cancer J from Scientific American 5: 16–17, 1999.
Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80: 219–230, 1999.
Boon T, Old LJ: Tumor antigens. Curr Opin Immunol 9: 681–683, 1997.
Sahin U, Koslowski M, Tureci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W, Pfreundschuh M: Expression of cancer testis genes in human brain tumors. Clin Cancer Res 6: 3916–3922, 2000.
Rights and permissions
Copyright information
© 2005 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
(2005). Immunophenotypic Characterization of Infiltrating Poly- and Mononuclear Cells in Childhood Brain Tumors. In: Molecular Markers of Brain Tumor Cells. Springer, Dordrecht. https://doi.org/10.1007/1-4020-2804-0_2
Download citation
DOI: https://doi.org/10.1007/1-4020-2804-0_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-2781-9
Online ISBN: 978-1-4020-2804-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)